

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

MONSANTO CO /NEW/
Form 10-Q
January 09, 2006

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended Nov. 30, 2005

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-16167

MONSANTO COMPANY

(Exact name of registrant as specified in its charter)

Delaware 43-1878297
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)

800 North Lindbergh Blvd., 63167
St. Louis, MO (Zip Code)
(Address of principal executive offices)

(314) 694-1000
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 269,376,062 shares of Common Stock, \$0.01 par value, outstanding as of Jan. 3, 2006.

MONSANTO COMPANY

F

TABLE OF CONTENTS

PART I--FINANCIAL INFORMATION

Item 1.	Financial Statements Statement of Consolidated Operations Condensed Statement of Consolidated Financial Position Statement of Consolidated Cash Flows Notes to Consolidated Financial Statements
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Overview Results of Operations -- First Quarter Fiscal Year 2006 Seeds and Genomics Segment Agricultural Productivity Segment Restructuring Financial Condition, Liquidity, and Capital Resources Outlook Critical Accounting Policies and Estimates New Accounting Standards Cautionary Statements Regarding Forward-Looking Statements
Item 3.	Quantitative and Qualitative Disclosures About Market Risk
Item 4.	Controls and Procedures

PART II--OTHER INFORMATION

Item 1.	Legal Proceedings
Item 1A.	Risk Factors
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
Item 5.	Other Information
Item 6.	Exhibits

SIGNATURE

EXHIBIT INDEX

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

PART I--FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The Statement of Consolidated Operations of Monsanto Company and its consolidated subsidiaries for the three months ended Nov. 30, 2005, and Nov. 30, 2004, the Condensed Statement of Consolidated Financial Position as of Nov. 30, 2005, and Aug. 31, 2005, the Statement of Consolidated Cash Flows for the three months ended Nov. 30, 2005, and Nov. 30, 2004, and related Notes to Consolidated Financial Statements follow. Unless otherwise indicated, "Monsanto" and the "company" are used interchangeably to refer to Monsanto Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context. Monsanto includes the operations, assets and liabilities that were previously

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

the agricultural business of Pharmacia Corporation, which is now a subsidiary of Pfizer Inc. Unless otherwise indicated, "earnings (loss) per share" and "per share" mean diluted earnings (loss) per share. In the notes to the consolidated financial statements, all dollars are expressed in millions, except per share amounts. Unless otherwise indicated, trademarks owned or licensed by Monsanto or its subsidiaries are shown in all capital letters. Unless otherwise indicated, references to "ROUNDUP herbicides" mean ROUNDUP branded herbicides, excluding all lawn-and-garden herbicides, and references to "ROUNDUP and other glyphosate-based herbicides" exclude all lawn-and-garden herbicides.

2

MONSANTO COMPANY

Statement of Consolidated Operations

Unaudited

(Dollars in millions, except per share amounts)

Net Sales

Cost of goods sold

Gross Profit

Operating Expenses:

Selling, general and administrative expenses

Research and development expenses

Acquired in-process research and development (see Note 3)

Restructuring charges

Total Operating Expenses

Income from Operations

Interest expense

Interest income

Solutia-related expenses (see Note 15)

Other expense (income) -- net

Income (Loss) from Continuing Operations Before Income Taxes

Income tax provision (benefit)

Income (Loss) from Continuing Operations

Discontinued Operations (see Note 17):

Income (loss) from operations of discontinued businesses

Income tax benefit

Income on Discontinued Operations

Net Income (Loss)

Basic Earnings (Loss) per Share:

Income (loss) from continuing operations

Income on discontinued operations

Net Income (Loss)

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Diluted Earnings (Loss) per Share:
 Income (loss) from continuing operations
 Income on discontinued operations

 Net Income (Loss)

Weighted Average Shares Outstanding:
 Basic
 Diluted

Dividends per Share

The accompanying notes are an integral part of these consolidated financial statements.

3

MONSANTO COMPANY

 Condensed Statement of Consolidated Financial Position

Unaudited

As o

(Dollars in millions, except share amounts)

Assets

Current Assets:

Cash and cash equivalents	\$ 1
Short-term investments	
Trade receivables -- net of allowances of \$289 and \$275, respectively	1
Miscellaneous receivables	
Deferred tax assets	
Inventories (see Note 6)	1
Assets of discontinued operations (see Note 17)	
Other current assets	

 Total Current Assets

Property, Plant and Equipment -- Net

Goodwill (see Note 7)

Other Intangible Assets -- Net (see Note 7)

Noncurrent Deferred Tax Assets

Other Assets

 Total Assets

Liabilities and Shareowners' Equity

Current Liabilities:

Short-term debt	\$
Accounts payable	
Income taxes payable	
Accrued compensation and benefits	
Accrued marketing programs	

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Deferred revenues	
Grower accruals	
Contingent purchase price -- Seminis (see Note 3)	
Liabilities of discontinued operations (see Note 17)	
Miscellaneous short-term accruals	

Total Current Liabilities	2
Long-Term Debt	1
Postretirement Liabilities	
Long-Term Portion of Solutia-Related Reserve (see Note 15)	
Other Liabilities	
Commitments and Contingencies (see Note 15)	
Shareowners' Equity:	
Common stock (authorized: 1,500,000,000 shares, par value \$0.01)	
Issued 281,778,117 and 280,851,349 shares, respectively;	
Outstanding 269,077,573 and 268,191,257 shares, respectively	
Treasury stock, 12,700,544 and 12,660,092 shares, respectively, at cost	
Additional contributed capital	8
Retained deficit	(1
Accumulated other comprehensive loss	
Reserve for ESOP debt retirement	

Total Shareowners' Equity	5

Total Liabilities and Shareowners' Equity	\$ 11
=====	

The accompanying notes are an integral part of these consolidated financial statements.

4

MONSANTO COMPANY F

Statement of Consolidated Cash Flows

Unaudited

(Dollars in millions)

Operating Activities:

Net Income (Loss)

Adjustments to reconcile cash provided (required) by operations:

 Items that did not require (provide) cash:

 Depreciation and amortization expense

 Bad-debt expense

 Stock-based compensation expense (see Note 11)

 Tax benefit on employee stock options

 Excess tax benefits from stock-based compensation (see Note 11)

 Deferred income taxes

 Equity affiliate expense -- net

 Solutia-related charge (see Note 15)

 Other items that did not require (provide) cash

Changes in assets and liabilities that provided (required) cash, net of acquisitions:

 Trade receivables

 Inventories

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Accounts payable and accrued liabilities
PCB litigation settlement proceeds
Solutia-related payments (see Note 15)
Pension contributions
Other items

Net Cash Provided by Operating Activities

Cash Flows Provided (Required) by Investing Activities:

Purchases of short-term investments
Maturities of short-term investments
Acquisition of businesses, net of cash acquired
Technology and other investments
Capital expenditures
Other investments and property disposal proceeds

Net Cash Provided (Required) by Investing Activities

Cash Flows Provided (Required) by Financing Activities:

Net change in financing with less than 90-day maturities
Short-term debt proceeds
Short-term debt reductions
Long-term debt proceeds
Long-term debt reductions
Payments on other financing
Treasury stock purchases
Stock option exercises
Excess tax benefits from stock-based compensation (see Note 11)
Dividend payments

Net Cash Required by Financing Activities

Net Increase in Cash and Cash Equivalents

Cash and Cash Equivalents at Beginning of Period

Cash and Cash Equivalents at End of Period

See Note 14 -- Supplemental Cash Flow Information -- for further details.

The accompanying notes are an integral part of these consolidated financial statements.

5

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

NOTE 1. BACKGROUND AND BASIS OF PRESENTATION

Monsanto Company, with its subsidiaries, is a leading global provider of agricultural products for farmers. Monsanto produces leading seed brands, including DEKALB, ASGROW, SEMINIS and STONEVILLE, and develops biotechnology traits that assist farmers in controlling insects and weeds. Monsanto provides other seed companies with genetic material and biotechnology traits for their seed brands. The company also manufactures ROUNDUP herbicide and other

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

herbicides. Monsanto's seeds, biotechnology trait products and herbicides provide growers with solutions that improve productivity, reduce the costs of farming, and produce healthier foods for consumers and better feed for animals. Monsanto also provides lawn-and-garden herbicide products for the residential market and animal agricultural products focused on improving dairy cow productivity and swine genetics.

Monsanto manages its business in two segments: Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and traits businesses and genetic technology platforms. The Agricultural Productivity segment consists of the crop protection products (ROUNDUP and other glyphosate-based herbicides and selective chemistries), animal agriculture businesses and lawn-and-garden herbicide products.

In second quarter 2005, the company committed to a plan to sell the environmental technologies businesses, and in fourth quarter 2005, substantially all of these businesses were sold. In fiscal year 2004, the company announced plans to exit the European breeding and seed business for wheat and barley and to discontinue the plant-made pharmaceuticals program, and the assets associated with the company's European wheat and barley business were sold. As a result of these exit plans, financial data for these businesses have been presented as discontinued operations as outlined below. The financial statements have been recast and prepared in compliance with the provisions of Statement of Financial Accounting Standards (SFAS) No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (SFAS 144). Accordingly, for the three months ended Nov. 30, 2005, and Nov. 30, 2004, the Statement of Consolidated Operations has been conformed to this presentation. Also under the guidance of SFAS 144, the remaining assets and liabilities of the environmental technologies businesses have been separately presented on the Condensed Statement of Consolidated Financial Position as of Nov. 30, 2005, and Aug. 31, 2005. The European wheat and barley business and plant-made pharmaceuticals program were previously reported as part of the Seeds and Genomics segment, and the environmental technologies businesses were previously reported as part of the Agricultural Productivity segment. See Note 17 -- Discontinued Operations -- for further details.

The accompanying consolidated financial statements have not been audited but have been prepared in conformity with accounting principles generally accepted in the United States for interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, these unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. This Report on Form 10-Q should be read in conjunction with Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005. Financial information for the first three months of fiscal year 2006 should not be annualized because of the seasonality of the company's business.

NOTE 2. NEW ACCOUNTING STANDARDS

In September 2005, the Financial Accounting Standards Board (FASB) reached a final consensus on Emerging Issues Task Force (EITF) Issue No. 04-13, Accounting for Purchases and Sales of Inventory with the Same Counterparty (EITF 04-13). EITF 04-13 concludes that two or more legally separate exchange transactions with the same counterparty should be combined and considered as a single arrangement for purposes of applying Accounting Principles Board (APB) Opinion No. 29, Accounting for Nonmonetary Transactions, when the transactions were entered into in contemplation of one another. The consensus contains several indicators to be considered in assessing whether two transactions are entered into in contemplation of one another. If, based on consideration of the indicators and the substance of the arrangement, two transactions are combined

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

and considered a single arrangement, an exchange of finished goods inventory for either raw material inventory or work-in-process inventory should be accounted for at fair value. The provisions of EITF 04-13 are effective for transactions beginning in Monsanto's fourth quarter 2006. The company is currently evaluating the impact of EITF 04-13 on the consolidated financial statements.

6

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections (SFAS 154). SFAS 154 requires retrospective application to prior-period financial statements of changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS 154 also redefines "restatement" as the revising of previously issued financial statements to reflect the correction of an error. This statement is effective for accounting changes and corrections of errors made in fiscal years beginning after Dec. 15, 2005. The company does not believe that the adoption of SFAS 154 will have a material impact on the consolidated financial statements.

In March 2005, the FASB issued Interpretation No. 47, Accounting for Conditional Asset Retirement Obligations (FIN 47) to clarify the term "conditional asset retirement" as used in SFAS No. 143, Accounting for Asset Retirement Obligations. FIN 47 requires that a liability be recognized for the fair value of a conditional asset retirement obligation when incurred, if the fair value of the liability can be reasonably estimated. Uncertainty about the timing or method of settlement of a conditional asset retirement obligation would be factored into the measurement of the liability when sufficient information exists. This interpretation is effective no later than the end of fiscal years ending after Dec. 15, 2005. Accordingly, Monsanto will adopt FIN 47 no later than fourth quarter of fiscal year 2006. The company does not believe that the adoption of FIN 47 will have a material impact on the consolidated financial statements.

In December 2004, the FASB issued FASB Staff Position No. 109-1, Application of FASB Statement No. 109 (SFAS 109), Accounting for Income Taxes, to the Tax Deduction on Qualified Production Activities Provided by the American Jobs Creation Act of 2004 (FSP 109-1). FSP 109-1 clarifies that the manufacturer's deduction provided for under the American Jobs Creation Act of 2004 (AJCA) should be accounted for as a special deduction in accordance with SFAS 109 and not as a tax rate reduction. The adoption of FSP 109-1 had no impact on Monsanto's consolidated financial statements in 2005 because the manufacturer's deduction is not available to Monsanto until fiscal year 2006. The company is currently evaluating the effect that the manufacturer's deduction will have in 2006 and subsequent years. The FASB also issued FASB Staff Position No. 109-2, Accounting and Disclosure Guidance for the Foreign Earnings Repatriation Provision within the American Jobs Creation Act of 2004 (FSP 109-2). The AJCA introduced a special one-time dividends received deduction on the repatriation of certain foreign earnings to a U.S. taxpayer (repatriation provision), provided certain criteria are met. FSP 109-2 provides accounting and disclosure guidance for the repatriation provision. The range of possible amounts that the company is currently considering eligible for repatriation is between zero and \$500 million. See Note 8 -- Income Taxes -- for additional disclosures in accordance with FSP 109-2.

NOTE 3. BUSINESS COMBINATIONS

2006 Acquisitions: In September 2005, Monsanto's American Seeds, Inc. (ASI) subsidiary acquired five regional U.S. seed companies in separate transactions for an aggregate purchase price of \$53 million (net of cash acquired), inclusive of transaction costs of \$2 million. Four of the five companies acquired are the shareowners of the CORE Group, an association of family-based seed companies that serve farmers throughout the Corn Belt, which primarily encompasses several states in the north central plains region. Those four companies are Fontanelle Hybrids, Inc., Trelay Seed Company, Stone Seed Company, and Stewart Seeds, Inc. (collectively, "the CORE Group"). In the fifth transaction, ASI acquired Specialty Hybrids, Inc., a company serving the Eastern Corn Belt. These acquisitions are expected to further bolster ASI's ability to directly serve farmer-customers with a technology-rich, locally-oriented business model. The transactions were completed on Sept. 1, 2005, from which time the results of these acquisitions were included in the company's consolidated financial statements. Pro forma information related to these acquisitions is not presented because the impact of these acquisitions, either individually or in the aggregate, on the company's consolidated results of operations is not considered to be significant.

For all fiscal year 2006 acquisitions described above, the business operations of the acquired entities were included in the Seeds and Genomics segment. These acquisitions were accounted for as purchase transactions. Accordingly, the assets and liabilities of the acquired entities were recorded at their estimated fair values at the dates of the acquisitions. The preliminary purchase price allocations for all fiscal year 2006 acquisitions as of Nov. 30, 2005, are subject to adjustment upon the completion of valuations and are summarized in the aggregate in the following table. Further, other assets and liabilities may be identified to which a portion of the purchase price could be allocated.

7

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

(Dollars in millions)

Tangible Assets
Goodwill
Other Intangible Assets
Total Assets Acquired
Total Liabilities Assumed
Net Assets Acquired

The primary items that generated the goodwill were the premiums paid by the company for the right to control the businesses acquired, including the

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

direct-to-farmer and farmer-dealer distribution models, and the value of the acquired assembled workforces. None of the goodwill is deductible for tax purposes.

The acquired identifiable intangible assets of \$19 million have a weighted-average useful life of approximately seven years. Intangible assets are comprised of acquired customer relationships of \$13 million to be amortized on a straight-line basis over seven years, trademarks and trade names of \$5 million to be amortized on a straight-line basis over lives ranging from seven to 10 years, and covenants not-to-compete of \$1 million to be amortized on a straight-line basis over five years.

2005 Acquisitions: In first quarter fiscal year 2005, Monsanto acquired the canola seed businesses of Advanta Seeds (Advanta) from Advanta B.V., including the ADVANTA SEEDS brand in Canada and the INTERSTATE seed brand in the United States, for \$52 million in cash (net of cash acquired), inclusive of transaction costs of \$2 million. The transaction was completed on Sept. 8, 2004, from which time the operating results of this acquisition were included in the company's consolidated financial statements.

In November 2004, ASI acquired Channel Bio Corp. for \$104 million in cash (net of cash acquired) and \$15 million in liabilities paid in second quarter 2005. In third quarter 2005, ASI, through its Channel Bio subsidiary, acquired NC+ Hybrids, Inc. for \$40 million in cash (net of cash acquired). In addition to these purchase price amounts, ASI paid transaction costs of \$4 million for these acquisitions. Channel Bio and NC+ Hybrids are U.S. seed companies that sell, market and distribute primarily corn and soybean seeds. The Channel Bio transaction was completed on Nov. 15, 2004, from which time the operating results of this acquisition were included in the company's consolidated financial statements. The NC+ Hybrids transaction was completed on March 1, 2005, from which time the operating results of this acquisition were included in the company's consolidated financial statements.

In third quarter fiscal year 2005, Monsanto acquired Seminis, Inc. for \$1.0 billion in cash (net of cash acquired), inclusive of transaction costs of \$23 million, and paid \$495 million for the repayment of its outstanding debt. The acquisition was completed on March 23, 2005, from which time the operating results of this acquisition were included in the company's consolidated financial statements. Marinet Investments, LLC, which prior to the closing was a holder of co-investment rights in Seminis, elected to reduce the cash payment to which it was entitled upon completion of the transaction by \$50 million in exchange for a contingent payment of up to \$125 million based on the achievement of certain cumulative net sales targets over the 36-month period ending Sept. 30, 2007, or certain other factors. The cash portion of the acquisition was funded with cash on hand plus commercial paper borrowings of \$600 million issued in March 2005. Prior to the closing of the transaction, Seminis initiated a tender offer to redeem all of its outstanding 10 1/4% Senior Subordinated Notes. In April 2005, payments totaling \$390 million were made to settle tender offers and were funded with commercial paper borrowings.

In order to enhance connections among Monsanto and Seminis employees, including the sharing of technology advancements, Monsanto is finalizing plans to integrate certain support services of Seminis with its other businesses. In conjunction with this integration, in September 2005, Monsanto and the chief executive officer of Seminis agreed that he would assist in the integration and resign by Dec. 31, 2005. As a result, Monsanto determined that the timing of the contingent payment discussed above has been accelerated and will be payable in second quarter 2006. A \$125 million liability has been recorded as of Nov. 30, 2005, resulting in additional purchase price and goodwill.

In third quarter fiscal year 2005, Monsanto acquired Emergent Genetics, Inc. and Emergent Genetics India Ltd. (collectively, "Emergent") for \$305 million (net of

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

cash acquired), inclusive of transaction costs of \$8 million. The transaction was completed on April 5, 2005, from which time the operating results of this acquisition were included in the company's consolidated financial statements.

8

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

The cash portion of the acquisition was funded with \$284 million of commercial paper borrowings issued in April 2005. Debt of \$16 million was also assumed in the transaction.

For all fiscal year 2005 acquisitions described above, the business operations of the acquired entities were included in the Seeds and Genomics segment. These acquisitions were accounted for as purchase transactions. Accordingly, the assets and liabilities of the acquired entities were recorded at their estimated fair values at the dates of the acquisitions. The purchase price allocations for Seminis, Emergent and NC+ Hybrids as of Nov. 30, 2005, are preliminary and are subject to adjustment upon finalization of integration or restructuring plans, as discussed below. Further, other assets and liabilities may be identified to which a portion of the purchase price could be allocated.

As of the acquisition dates, management began to assess and formulate plans to integrate or restructure the acquired entities. These activities are accounted for in accordance with EITF Issue No. 95-3, Recognition of Liabilities in Connection with a Purchase Business Combination, and primarily include the potential closure of facilities, the abandonment or redeployment of equipment, and employee terminations or relocations. In first quarter 2006, management finalized plans to integrate or restructure certain activities of Seminis and the Emergent India business. As a result, asset fair values were reduced by \$2 million, and additional liabilities of \$14 million were recorded, resulting in additional goodwill of \$16 million. The plans for Seminis and the Emergent India business include employee terminations and relocations, exiting certain product lines and facility closures. As of Nov. 30, 2005, estimated integration costs of \$21 million have been recognized as current liabilities in the purchase price allocations, and \$3 million has been charged against these liabilities, primarily related to payments for employee terminations and relocations.

Charges of \$12 million were recorded in first quarter 2005 for the write-off of acquired in-process R&D (IPR&D) related to the Advanta and Channel Bio acquisitions. Management believed that the technological feasibility of the IPR&D was not established and that the research had no alternative future uses. Accordingly, the amounts allocated to IPR&D were expensed immediately, in accordance with generally accepted accounting principles.

NOTE 4. RESTRUCTURING

Restructuring charges were recorded in the Statement of Consolidated Operations as follows:

(Dollars in millions)

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Restructuring Charges(1)

Loss from Continuing Operations Before Income Taxes
Income Tax Benefit

Income from Continuing Operations

Net Income

(1) The \$1 million of restructuring charges for the three months ended Nov. 30, 2004, was recorded in the Agricultural Productivity segment.

Fiscal Year 2004 Restructuring Plan

On Oct. 15, 2003, Monsanto announced plans to continue to reduce costs primarily associated with its agricultural chemistry business as that sector matures globally. Total restructuring actions approved under the fiscal year 2004 restructuring plan were estimated to be \$289 million pretax. These plans included: (1) reducing costs associated with the company's ROUNDUP herbicide business; (2) exiting the European breeding and seed business for wheat and barley; and (3) discontinuing the plant-made pharmaceuticals program. In fiscal year 2004, total restructuring charges related to these actions were \$165 million pretax (\$105 million aftertax). Additionally, the approved plan included a \$69 million impairment of goodwill in the global wheat business. In fiscal year 2005, the company incurred charges of \$6 million pretax to complete the restructuring actions under this plan.

In first quarter of fiscal year 2005, Monsanto recorded restructuring charges of \$1 million pretax related to workforce reductions. The company also recorded a deferred tax benefit of \$106 million, of which \$20 million was recorded in continuing operations and the remaining \$86 million was recorded in discontinued operations. The \$20 million tax benefit recorded in continuing operations was related to the impairment of goodwill in the global wheat business as part of

9

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

the fiscal year 2004 restructuring plan. As such, the benefit amount recorded in continuing operations is reflected in the table above. See Note 8 -- Income Taxes -- and Note 17 -- Discontinued Operations -- for further discussion of the \$86 million tax benefit recorded in discontinued operations.

The following table displays a roll forward of the remaining liability established for restructuring expense from Aug. 31, 2005, to Nov. 30, 2005:

(Dollars in millions)

Continuing Operations:

Beginning liability as of Aug. 31, 2005
Restructuring liability
Cash payments

Ending liability as of Nov. 30, 2005

NOTE 5. CUSTOMER FINANCING PROGRAMS

In April 2002, Monsanto established a revolving financing program to provide financing of up to \$500 million for selected customers in the United States through a third-party specialty lender. The funding availability may be less than \$500 million if certain program requirements are not met. Under the financing program, Monsanto originates customer loans on behalf of the lender, which is a special purpose entity (SPE) that Monsanto consolidates, pursuant to Monsanto's credit and other underwriting guidelines approved by the lender. Monsanto services the loans and provides a first-loss guarantee of up to \$100 million. Following origination, the lender transfers the loans to multi-seller commercial paper conduits through a nonconsolidated qualifying special purpose entity (QSPE). Monsanto accounts for this transaction as a sale, in accordance with SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishment of Liabilities (SFAS 140).

Monsanto has no ownership interest in the lender, in the QSPE, or in the loans. However, because Monsanto substantively originates the loans through the SPE (which it consolidates) and partially guarantees and services the loans, Monsanto accounts for the program as if it were the originator of the loans and the transferor selling the loans to the QSPE.

Monsanto records its guarantee liability at a value that approximates fair value (except that it does not discount credit losses because of the short-term nature of the loans), primarily driven by expected future credit losses. Monsanto does not recognize any servicing asset or liability because the servicing fee is adequate compensation for the servicing activities. Discounts on the sale of the customer loans and servicing revenues collected and earned were not significant during the three months ended Nov. 30, 2005, and Nov. 30, 2004.

Proceeds from customer loans sold through the financing program totaled \$18 million for first quarter 2006 and \$60 million for first quarter 2005. These proceeds are included in net cash provided by operations in the Statement of Consolidated Cash Flows. The loan balance outstanding as of Nov. 30, 2005, and Aug. 31, 2005, was \$119 million and \$171 million, respectively. The first-loss guarantee will be in place throughout the financing program. Loans are considered delinquent when payments are 31 days past due. If a customer fails to pay an obligation when due, Monsanto would incur a liability to perform under the first-loss guarantee. As of Nov. 30, 2005, and Aug. 31, 2005, less than \$1 million of loans sold through this financing program were delinquent. As of Nov. 30, 2005, and Aug. 31, 2005, Monsanto recorded its guarantee liability at less than \$1 million, primarily based on the company's historical collection experience with these customers and a current assessment of credit exposure. Adverse changes in the actual loss rate would increase the liability. If Monsanto is called upon to make payments under the first-loss guarantee, it would have the benefit under the financing program of any amounts subsequently collected from the customer.

In January 2003, the FASB issued FASB Interpretation No. 46, Consolidation of Variable Interest Entities (FIN 46), and amended it by issuing FIN 46R in December 2003. The SPE is included in Monsanto's consolidated financial statements. Because QSPEs are excluded from the scope of FIN 46R and Monsanto does not have the unilateral right to liquidate the QSPE, this interpretation does not have an effect on Monsanto's accounting for the U.S. customer financing program.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

In November 2004, Monsanto entered into an agreement with a lender to establish a program to provide financing of up to \$40 million for selected customers in Brazil. The agreement, as amended in May 2005, qualifies for sales treatment under SFAS 140. Accordingly, proceeds from the transfer of receivables subsequent to the May 2005 amendment are included in net cash provided by operations in the Statement of Consolidated Cash Flows. Proceeds from customer loans sold through the financing program totaled \$18 million for first quarter 2006. There were no loans sold through the program in first quarter 2005. The loan balance outstanding as of Nov. 30, 2005, and Aug. 31, 2005, was \$37 million and \$22 million, respectively. Monsanto provides a full guarantee of the loans in the event of customer default. The liability for the guarantee is recorded at an amount that approximates fair value and is primarily based on the company's historical collection experience with customers that participate in the program. The guarantee liability recorded by Monsanto was \$1 million as of Nov. 30, 2005, and less than \$1 million as of Aug. 31, 2005. If performance is required under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.

NOTE 6. INVENTORIES

Components of inventories were:

	As

(Dollars in millions)	
	\$
Finished Goods	
Goods In Process	
Raw Materials and Supplies	
	\$
Inventories at FIFO Cost	
Excess of FIFO over LIFO Cost	
	\$
Total	==

In November 2004, the FASB issued SFAS No. 151, Inventory Costs -- an amendment of ARB No. 43, Chapter 4 (SFAS 151), to clarify that abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage) should be recognized as current period charges and to require the allocation of fixed production overhead to the costs of conversion based on the normal capacity of the production facilities. SFAS 151 was effective for Monsanto for inventory costs incurred after Sept. 1, 2005. The adoption of SFAS 151 did not have a material impact on the company's consolidated financial statements.

NOTE 7. GOODWILL AND OTHER INTANGIBLE ASSETS

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Changes in the net carrying amount of goodwill for the first quarter of fiscal year 2006, by segment, are as follows:

(Dollars in millions)	Seeds and Genomics
Balance as of Aug. 31, 2005	\$ 1,183
Acquisition Activity (see Note 3)	185
Effect of Foreign Currency Translation Adjustments	--
Balance as of Nov. 30, 2005	\$ 1,368

Information regarding the company's other intangible assets is as follows:

(Dollars in millions)	As of Nov. 30, 2005			As of A	
	Carrying Amount	Accumulated Amortization	Net	Carrying Amount	Ac Am
Acquired Germplasm	\$ 927	\$ (498)	\$ 429	\$ 926	\$
Acquired Biotechnology					
Intellectual Property	652	(306)	346	648	
Trademarks and Trade Names	198	(37)	161	193	
Customer Relationships	189	(9)	180	176	
Other	33	(14)	19	32	
Total	\$ 1,999	\$ (864)	\$ 1,135	\$ 1,975	\$

11

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

The increases in other intangible assets during the first quarter of 2006 primarily resulted from the acquisitions described in Note 3 -- Business Combinations.

Total amortization expense of other intangible assets was \$42 million in first quarter of fiscal year 2006 and \$28 million in first quarter of fiscal year 2005. Estimated intangible asset amortization expense for each of the five succeeding fiscal years has not changed significantly from the amounts disclosed in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005.

NOTE 8. INCOME TAXES

The American Jobs Creation Act of 2004 (AJCA) was enacted on Oct. 22, 2004, and

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

created a temporary incentive for U.S. multinationals to repatriate accumulated earnings outside the United States by providing an 85 percent dividends received deduction for certain dividends from controlled foreign corporations. Monsanto may elect to apply this provision to qualifying earnings repatriations in fiscal year 2006. As of Nov. 30, 2005, Monsanto has not recorded deferred taxes on foreign earnings because any taxes on dividends would be substantially offset by foreign tax credits or because Monsanto intends to reinvest those earnings indefinitely. Due to the complexity of the repatriation provision, the company is still evaluating the effects of this one-time incentive. The range of possible amounts that the company is currently considering eligible for repatriation is between zero and \$500 million. Accordingly, the company expects, based on the information presently available, that it may record a tax liability based on the 5.25% statutory rate in the AJCA. However, the actual cost to the company is dependent on a number of factors that are currently being analyzed. Therefore, as of Nov. 30, 2005, the related potential range of income tax effects of such repatriation cannot be reasonably estimated.

The sale of the European wheat and barley business in fiscal year 2004 generated a tax loss deductible in either the United Kingdom or the United States. As of Aug. 31, 2004, a deferred tax asset had not been recorded for the tax loss incurred in the United States because of the existence of a number of uncertainties. These uncertainties diminished with the enactment of the AJCA. As a result, Monsanto recorded a deferred tax benefit of \$106 million in first quarter 2005. Of this tax benefit, \$20 million was recorded in continuing operations related to the impairment of goodwill in the global wheat business recorded in first quarter 2004. The remaining \$86 million recorded in discontinued operations was primarily related to the goodwill impairment loss at the date of adoption of SFAS No. 142, Goodwill and Other Intangible Assets (SFAS 142), on Jan. 1, 2002, which was recorded as a cumulative effect of a change in accounting principle. The recognition of this tax benefit in the United States effectively precludes Monsanto from claiming any U.K. benefit for the U.K. tax loss. Accordingly, the U.K. deferred tax asset of \$71 million, which had a full valuation allowance against it, was written off during first quarter 2005.

NOTE 9. ACCOUNTING FOR DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

Monsanto's business and activities expose it to a variety of market risks, including risks related to changes in commodity prices for seed inventories purchased from growers, foreign-currency exchange rates, interest rates and, to a lesser degree, security prices and natural gas prices. These financial exposures are monitored and managed by the company as an integral part of its market risk management program. This program recognizes the unpredictability of financial markets and seeks to reduce the potentially adverse effects that market volatility could have on operating results. Monsanto's overall objective in holding derivatives is to minimize the risks by using the most effective methods to eliminate or reduce the effects of these exposures. Monsanto accounts for its derivatives in accordance with SFAS No. 133, Accounting for Derivative Instruments and Hedging Activities, and SFAS No. 149, Amendment of Statement 133 Derivative Instruments and Hedging Activities.

NOTE 10. POSTRETIREMENT BENEFITS -- PENSIONS, HEALTH CARE AND OTHER

The majority of Monsanto's employees are covered by noncontributory pension plans sponsored by the company. The company also provides certain postretirement health care and life insurance benefits for retired employees through insurance contracts. The company's net periodic benefit cost for pension benefits, and health care and other postretirement benefits include the following components:

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

Pension Benefits

(Dollars in millions)

Service Cost for Benefits Earned During the Period
 Interest Cost on Benefit Obligation
 Assumed Return on Plan Assets
 Amortization of Unrecognized Net Loss

Total Net Periodic Benefit Cost

Health Care and Other Postretirement Benefits

(Dollars in millions)

Service Cost for Benefits Earned During the Period
 Interest Cost on Benefit Obligation
 Amortization of Unrecognized Net Loss

Total Net Periodic Benefit Cost

Monsanto contributed \$61 million to its pension plans in first quarter 2006 and \$60 million in first quarter 2005. As of Nov. 30, 2005, management expects to make additional contributions of approximately \$1 million to the company's pension plans in fiscal year 2006. Pending management's assessment of 2006 results of operations, the company may reassess planned contributions to its pension plans.

NOTE 11. STOCK-BASED COMPENSATION PLANS

On Sept. 1, 2005, Monsanto adopted SFAS No. 123 (revised 2004), Share-Based Payment (SFAS 123R), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors based on estimated fair values. SFAS 123R supersedes Monsanto's previous accounting under APB Opinion No. 25, Accounting for Stock Issued to Employees, for periods beginning in fiscal 2006. In March 2005, the SEC issued Staff Accounting Bulletin No. 107 (SAB 107) relating to SFAS 123R. Monsanto has applied the provisions of SAB 107 in its adoption of SFAS 123R.

Monsanto adopted SFAS 123R using the modified prospective transition method. Under this method, the company's consolidated financial statements as of and for the three months ended Nov. 30, 2005, reflect the impact of SFAS 123R, while the

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

consolidated financial statements for prior periods have not been restated to reflect, and do not include, the impact of SFAS 123R. Stock-based compensation expense recognized under SFAS 123R was \$13 million for first quarter 2006, which consisted of: (1) compensation expense for all unvested share-based awards outstanding as of Sept. 1, 2005, based on the grant date fair value estimated in accordance with the pro forma provisions of SFAS No. 123, Accounting for Stock-Based Compensation (SFAS 123) and (2) compensation expense for share-based awards granted subsequent to adoption based on the grant date fair value estimated in accordance with the provisions of SFAS 123R. Stock-based compensation expense recognized during the period is based on the value of the portion of share-based payment awards that are ultimately expected to vest. Compensation cost capitalized as part of inventory was immaterial for first quarter 2006. SFAS 123R amends SFAS No. 95, Statement of Cash Flows, to require that excess tax benefits be reported as a financing cash inflow rather than as a reduction of taxes paid, which is included within operating cash flows. The following table shows the impact of the adoption of SFAS 123R on the Statement of Consolidated Operations and the Statement of Consolidated Cash Flows.

13

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

(Dollars in millions, except per share amounts)

Cost of Goods Sold

Selling, General and Administrative Expenses(1)

Research and Development Expenses

Total stock-based compensation expense included in operating expenses

Loss From Continuing Operations Before Income Taxes

Income Tax Benefit

Net Loss

Basic and Diluted Loss per Share

Net Cash Required by Operating Activities

Net Cash Provided by Financing Activities

(1) Includes \$3 million related to share-based awards for which compensation expense was being recognized prior to the adoption of SFAS 123R.

Plan Descriptions: Share-based awards are designed to reward employees for their long-term contributions to the company and provide incentives for them to remain with the company. Monsanto issues stock option awards, restricted stock, and restricted stock units with performance conditions under three fixed stock plans. Under the Monsanto Company Long-Term Incentive Plan, as amended (LTIP), formerly known as the Monsanto 2000 Management Incentive Plan, the company may

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

grant awards to key officers, directors and employees of Monsanto, including stock options, of up to 39.3 million shares of Monsanto common stock. Other employees may be granted options under the Monsanto Company Broad-Based Stock Option Plan (Broad-Based Plan), which permits the granting of a maximum of 2.7 million shares of Monsanto common stock to employees other than officers and other employees subject to special reporting requirements. In January 2005, shareholders approved the Monsanto Company 2005 Long-Term Incentive Plan (2005 LTIP), under which the company may grant awards to key officers, directors and employees of Monsanto, including stock options, of up to 12.0 million shares of Monsanto common stock. As of Nov. 30, 2005, no awards have been granted under the 2005 LTIP.

Under the plans, the grant price of any option is the average of the high price and low price of the company's common stock on the day before the grant date. The plans provide that the term of any option granted may not exceed 10 years and that each option may be exercised for such period as may be specified by the People and Compensation Committee of the board of directors or by the delegate who administers the plans. Generally, the options vest over three years, with one-third of the total award vesting each year. Grants of restricted stock generally vest at the end of a three-year or five-year service period. Restricted stock units represent the right to receive a number of shares of restricted stock dependent upon vesting requirements. Vesting is subject to Monsanto's attainment of specified performance criteria during the designated performance period and the employees' continued employment during the designated service period. Compensation expense for stock options, restricted stock and restricted stock units is measured at fair value on the date of grant, net of estimated forfeitures, and recognized over the vesting period of the award.

Certain Monsanto employees outside the United States may receive stock appreciation rights as part of Monsanto's stock compensation plans. These rights entitle those employees to receive a cash amount determined by the appreciation in the fair market value of the company's common stock between the date of the award and the date of exercise. The fair value of these awards was \$2 million as of Nov. 30, 2005. The fair value is remeasured at the end of each reporting period and compensation expense is recognized over the requisite service period in accordance with SFAS 123R.

Monsanto also issues share-based awards under the Monsanto Non-Employee Director Equity Incentive Compensation Plan (Director Plan) for directors who are not employees of Monsanto or its affiliates. Under the Director Plan, half of the annual retainer for each nonemployee director is paid in the form of deferred stock -- shares of common stock to be delivered at a specified future time. The remainder is payable, at the election of each director, in the form of restricted common stock, deferred common stock, current cash and/or deferred cash. The Director Plan also provides that a nonemployee director will receive a grant of three thousand shares of restricted stock upon commencement of service as a member of Monsanto's board of directors. Awards of deferred stock and restricted stock under the Director Plan are automatically granted under the LTIP as provided for in the Director Plan. There were no share-based liabilities paid under the Director Plan in first quarter 2006 or 2005.

14

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

A summary of the status of Monsanto's stock option plans for the first quarter of fiscal year 2006 follows:

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

	Shares
Balance Outstanding as of Aug. 31, 2005	14,682,796
Granted	2,944,560
Exercised	(872,458)
Forfeited	(49,554)
Balance Outstanding as of Nov. 30, 2005	16,705,344

Monsanto stock options outstanding and exercisable as of Nov. 30, 2005, are summarized by exercise price as follows:

Range of Exercise Prices	Options Outstanding			Aggregate Intrinsic Value(1) (dollars in millions)	Options Outstanding Shares
	Weighted-Average Remaining Contractual Life (years)	Weighted-Average Exercise Price per Share	Weighted-Average		
\$14.66 - \$20.00	6.8	\$17.64	\$371	4,558,631	
\$20.01 - \$40.00	6.7	\$31.41	\$149	1,841,500	
\$40.01 - \$60.00	9.2	\$48.41	\$158	1,094,181	
\$60.01 - \$73.43	9.6	\$70.35	--	--	
	16,705,344		\$678	7,494,312	

(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, based on Monsanto's closing stock price of \$73.27 as of Nov. 30, 2005, which would have been received by the option holders had all option holders exercised their options as of that date.

The number of options exercisable and the corresponding weighted-average exercise price were 7,143,654 and \$22.82 as of Aug. 31, 2005. The total pre-tax intrinsic value of options exercised during the three months ended Nov. 30, 2005, and 2004, was \$34 million and \$40 million, respectively. Pre-tax unrecognized compensation expense for stock options, net of estimated forfeitures, was \$81 million as of Nov. 30, 2005, and will be recognized as expense over a weighted-average period of 2.3 years.

A summary of the status of Monsanto's restricted stock and restricted stock units compensation plans for the first quarter of fiscal year 2006 follows:

Restricted	Weighted-Average Grant Date	Restricti
------------	-----------------------------	-----------

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

	Stock	Fair Value	Stock
Nonvested as of Aug. 31, 2005	193,200	\$25.02	136
Granted	22,500	\$58.65	59
Vested	107,000	\$17.12	—
Forfeited	--	--	—
Nonvested as of Nov. 30, 2005	108,700	\$39.75	195

The total fair value of restricted stock that vested during first quarter 2006 and 2005 was \$2 million and less than one million, respectively. Pre-tax unrecognized compensation expense, net of estimated forfeitures, for nonvested restricted stock and restricted stock units was \$3 million and \$15 million, respectively, as of Nov. 30, 2005, which will be recognized as expense over the weighted-average remaining requisite service periods. The weighted-average remaining requisite service periods for nonvested restricted stock and restricted stock units were 3.0 years and 2.0 years, respectively, as of Nov. 30, 2005.

Valuation and Expense Information under SFAS 123R: Upon adoption of SFAS 123R, Monsanto began estimating the value of employee stock options on the date of grant using a lattice-binomial model. Prior to adoption of SFAS 123R, the value of employee stock options was estimated on the date of grant using the Black-Scholes model, for the disclosures of pro forma financial information required under SFAS 123. A lattice-binomial model requires the use of extensive actual employee exercise behavior data and a number of complex assumptions including volatility, risk-free interest rate and expected dividends. Expected volatilities utilized in the model are based on implied volatilities from traded options on Monsanto's stock and historical volatility of Monsanto's stock price. The expected life represents the weighted-average period the stock options are

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

expected to remain outstanding and is a derived output of the model. The lattice-binomial model incorporates exercise and post-vesting forfeiture assumptions based on an analysis of historical data. The following assumptions were used to calculate the estimated value of employee stock options:

	Three Mo
	2005
Assumptions	Lattice-binom
Expected Dividend Yield	1.2%
Expected Volatility	32% - 36%
Weighted-Average Volatility	33.2%
Risk-Free Interest Rates	4.2% - 4.58%
Weighted-Average Risk-Free Interest Rate	4.4%

Expected Option Life (in years)

5.9

NA = Not Applicable

The weighted-average estimated value of employee stock options granted during the first three months of fiscal years 2006 and 2005 was \$18.91 and \$9.94, respectively.

In accordance with the modified prospective transition method, Monsanto's consolidated financial statements for prior periods have not been restated and do not include the impact of SFAS 123R. Accordingly, no compensation expense related to stock option awards was recognized in the first quarter of fiscal year 2005, as all stock options granted had an exercise price equal to the fair market value of the underlying common stock on the date of grant. The following table shows the effect on net loss and loss per share as if the fair-value-based method of accounting had been applied to all outstanding and unvested stock option awards prior to adoption for SFAS 123R. Stock-based compensation included in net income in the first quarter of 2005 included expense for awards of restricted stock, restricted stock units, stock appreciation rights and awards granted under the Director Plan. For purposes of this pro forma disclosure, the estimated fair value of the award is assumed to be expensed over the award's vesting periods using the Black-Scholes model.

(Dollars in millions, except per share amounts)

Net Loss:

As reported

Add: Stock-based compensation expense included in reported Net Loss, net of tax

Less: Total stock-based compensation expense determined under the fair-value-based method for awards, net of tax

Pro forma-----
Basic and Diluted Loss per Share:

As reported

Pro forma

For stock option awards with accelerated vesting provisions that are granted to retirement-eligible employees and to employees that become eligible for retirement subsequent to the grant date, Monsanto previously followed the guidance of APB 25 and SFAS 123, which allowed compensation costs to be recognized ratably over the vesting period of the award. SFAS 123R requires compensation costs to be recognized over the requisite service period of the award instead of ratably over the vesting period stated in the grant. For awards granted prior to adoption, the SEC clarified that companies should continue to follow the vesting method they had previously been using. As a result, for awards granted prior to adoption, Monsanto will continue to recognize compensation costs ratably over the vesting period with accelerated recognition of the unvested portion upon actual retirement. The impact of accelerated vesting on the pro forma disclosure shown above is immaterial. Monsanto will follow the guidance of SFAS 123R for awards granted subsequent to the adoption date.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Monsanto's income taxes currently payable have been reduced by the tax benefits from employee stock option exercises. These benefits totaled \$10 million and \$12 million for the three months ended Nov. 30, 2005, and 2004, respectively, and were recorded as an increase to additional paid-in capital.

16

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

NOTE 12. COMPREHENSIVE INCOME

Comprehensive income includes all nonshareowner changes in equity and consists of net income (loss), foreign currency translation adjustments, gains and losses on the foreign currency hedge of the company's net investment in a foreign subsidiary, net unrealized gains and losses on available-for-sale securities, additional minimum pension liability adjustments, and net accumulated derivative gains or losses on cash flow hedges not yet realized. Information regarding comprehensive income is as follows:

(Dollars in millions)

Comprehensive Income	\$
----------------------	----

The components of accumulated other comprehensive loss are as follows:

(Dollars in millions)

Accumulated Foreign Currency Translations	\$
Net Unrealized Gains on Investments, Net of Taxes	
Net Accumulated Derivative Loss, Net of Taxes	
Minimum Pension Liability, Net of Taxes	
Accumulated Other Comprehensive Loss	\$

NOTE 13. EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share (EPS) was computed using the weighted-average number of common shares outstanding during the period shown in the table below.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

For first quarter 2006, diluted EPS was computed taking into account the effect of dilutive potential common shares, as shown in the table below. Because Monsanto reported a loss from continuing operations for the three months ended Nov. 30, 2004, SFAS No. 128, Earnings per Share, requires diluted loss per share to be calculated using weighted-average common shares outstanding, excluding dilutive potential common shares. If diluted EPS were computed taking into account the effect of dilutive potential common shares, the number of shares that would be included in the calculation of dilutive EPS is noted in the table below. Potential common shares consist primarily of stock options using the treasury stock method and are excluded if their effect is antidilutive. Dilutive potential common shares noted below exclude stock options of approximately 0.1 million and 1.9 million for the three months ended Nov. 30, 2005, and Nov. 30, 2004, respectively. These potential common shares were excluded because the options' exercise prices were greater than the average market price of the common shares.

Weighted-Average Number of Common Shares
Dilutive Potential Common Shares

17

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

NOTE 14. SUPPLEMENTAL CASH FLOW INFORMATION

The effect of exchange rate changes on cash and cash equivalents was not material. Cash payments for interest and taxes were as follows:

(Dollars in millions)

Interest
Taxes

In first quarter fiscal year 2006, the company recognized noncash transactions related to acquisitions. See Note 3 -- Business Combinations -- for details of liabilities assumed in acquisitions.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

NOTE 15. COMMITMENTS AND CONTINGENCIES

Litigation and Indemnification: Monsanto is defending and prosecuting litigation in its own name. In addition, Monsanto is defending and prosecuting certain cases that were brought in Pharmacia's name and for which Monsanto assumed responsibility under the Separation Agreement (defined below). Such matters relate to a variety of issues. Some of the lawsuits seek damages in very large amounts, or seek to restrict the company's business activities. Information with respect to these lawsuits appears in Part I -- Item 3 -- Legal Proceedings in Monsanto's Report on Form 10-K for the fiscal year ended August 31, 2005, and in Part II -- Item 1 -- Legal Proceedings in this Report on Form 10-Q. While the ultimate liabilities resulting from such lawsuits may be significant to profitability in the period recognized, management does not anticipate they will have a material adverse effect on Monsanto's consolidated financial position or liquidity, excluding liabilities relating to Solutia.

On Dec. 4, 2000, Monsanto filed suit in the U.S. District Court for the Eastern District of Missouri for a declaratory judgment against Bayer CropScience AG, a subsidiary of Bayer AG, and its affiliates that four patents, which had been assigned to Bayer CropScience by Plant Genetics Systems, N.V. and which involve claims to truncated Bt technology, were invalid and not infringed by the MON810 corn product contained in YIELDGARD corn. Bayer CropScience counterclaimed to request royalties for prior sales of YIELDGARD corn and injunctive relief but later dismissed with prejudice its claims on three of the four patents in dispute and agreed not to sue Monsanto, its affiliates or its sublicensees under those patents for any of Monsanto's current commercial products. On Nov. 22, 2005, a jury returned a verdict in Monsanto's favor and determined that MON810 did not infringe the remaining patent at issue and that the patent was invalid. Monsanto intends to seek recovery from Bayer CropScience of its attorneys' fees involved in defending against the claims and an appeal will be taken by Bayer to overturn the trial court's judgment in favor of Monsanto.

Following receipt of a patent relating to bovine growth hormone, on Feb. 17, 2004, the Regents of the University of California (UC) filed suit against Monsanto in the U.S. District Court for the Northern District of California. As part of its order construing the terms of patent, the court has ruled that the claims are extremely broad. UC seeks damages, including a paid-up license, and an injunction for the alleged infringement of the patent by sales of Monsanto's POSILAC bovine somatotropin product. Monsanto has strong defenses to these claims, including non-infringement of the patent, and invalidity on multiple grounds including lack of enablement. On Dec. 16, 2005, the District Court granted in part and denied in part motions of the parties for summary judgment. As a result of numerous contested issues of fact, the case will proceed to jury trial on Feb. 27, 2006.

Solutia Inc.: The following discussion provides new and updated information regarding proceedings related to Solutia. Other information with respect to Solutia matters appears in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005. Pursuant to the Sept. 1, 2000, Separation Agreement between Monsanto and Pharmacia, as amended (Separation Agreement), Monsanto was required to indemnify Pharmacia for liabilities that Solutia assumed from Pharmacia under a Distribution Agreement entered into between those companies in connection with the spinoff of Solutia on Sept. 1, 1997, as amended (Distribution Agreement), to the extent that Solutia fails to pay, perform or discharge those liabilities.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

Those liabilities are referred to as "Solutia's Assumed Liabilities." Solutia's Assumed Liabilities may include, among others, litigation, environmental remediation, and certain retiree liabilities relating to individuals who were employed by Pharmacia prior to the Solutia spinoff.

Both immediately prior to and since its Chapter 11 filing, Solutia has failed to perform its obligations relating to some of Solutia's Assumed Liabilities. Monsanto believes Solutia is required to meet its obligations unless and until those obligations are discharged by the Bankruptcy Court. However, in order to protect Pharmacia's and Monsanto's interests until that issue is resolved, pursuant to Monsanto's obligation to indemnify Pharmacia and on an interim basis, Monsanto has assumed the management and defense of certain third-party tort litigation and funded some of Solutia's environmental obligations. In the process of managing such litigation and environmental liabilities, and through Monsanto's involvement in the bankruptcy process, Monsanto determined that it was probable that Monsanto would incur some expenses related to third-party tort litigation and environmental liabilities and that the amount of certain of these expenses could be reasonably estimated. In December 2004, Monsanto determined that it was appropriate to establish a reserve for such expenses based on the best estimates by Monsanto's management with input from its legal and other outside advisors. Accordingly, a charge in the amount of \$284 million (the "Solutia-related charge" or the "charge") was recorded in Monsanto's first quarter fiscal 2005 results. As of Nov. 30, 2005, \$232 million was recorded in the Condensed Statement of Consolidated Financial Position (\$49 million in current liabilities and \$183 million in other liabilities).

Monsanto believes that the Solutia-related charge represents the discounted cost that Monsanto would expect to incur in connection with these litigation and environmental matters. Monsanto expects to pay for these potential liabilities over time as the various legal proceedings are resolved and remediation is performed at the various environmental sites. Actual costs to Monsanto may differ materially from this estimate. Further, additional litigation or environmental matters that are not reflected in the charge may arise in the future, and Monsanto may also manage, settle, or pay judgments or damages with respect to litigation or environmental matters in order to mitigate contingent potential liability and protect Pharmacia and Monsanto, if Solutia refuses to do so.

Receivables of \$64 million were recorded as of Nov. 30, 2005 (\$27 million was recorded in miscellaneous receivables and \$37 million was recorded in other assets), for the anticipated insurance reimbursement of a portion of the \$150 million and \$400 million settlement amounts paid by Monsanto during August and September 2003. Monsanto expects these receivables to be paid over three years, in quarterly installments which began in March 2005.

In addition to the Solutia-related charge, Monsanto has incurred legal and other costs related to the Chapter 11 proceeding and its Solutia-related indemnification obligations to Pharmacia. These costs are expensed as incurred, because the potential future costs to Monsanto to protect its interests cannot be reasonably estimated. The legal and other costs, together with the Solutia-related charge recorded in first quarter 2005, are reflected in the Statement of Consolidated Operations as Solutia-related expenses.

The degree to which Monsanto may ultimately be responsible for the particular matters reflected in the charge or other of Solutia's Assumed Liabilities or Solutia-related expenses is uncertain, although, as described in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005, Monsanto announced on June 7, 2005, that it had reached an agreement in principle with Solutia and

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

the Official Committee of Unsecured Creditors for a proposal for Solutia's reorganization. Solutia has not filed a plan of reorganization, and thus any projection of the outcome of Monsanto's claims remains uncertain, but it is possible that Monsanto could receive equity in any reorganized Solutia in satisfaction or partial satisfaction of Monsanto's claims. However, discussions between and among the various parties involved in the Solutia bankruptcy are continuing, and any formal reorganization plan must ultimately be affirmed by several constituencies and the Bankruptcy Court.

On Dec. 16, 2005, Solutia filed a complaint against Pharmacia and Monsanto to recover alleged preferential transfers from Monsanto and avoid the transfers of certain liabilities allegedly fraudulently transferred to Solutia by Pharmacia and Monsanto. This complaint was filed by Solutia prior to a two-year statutory deadline from Solutia's Chapter 11 petition date (Dec. 17, 2003) to preserve rights, if any, of Solutia's bankruptcy estate. Concurrent with this filing, Solutia announced that (i) it filed this action to preserve the legal rights of Solutia's bankruptcy estate; (ii) Solutia has made no decision to pursue this action; and (iii) Solutia remains committed to the agreement in principle announced on June 7, 2005. The complaint is redundant in many respects to other pending actions filed against Monsanto and Pharmacia by other constituents in the case (including the Official Committee of Equity Security Holders and the Official Committee of Retirees). Monsanto remains committed to the agreement in

19

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

principle which would render this complaint moot if the agreement in principle becomes effective and binding.

Solutia Environmental Obligations: Included in the Solutia-related charge are amounts related to certain of Solutia's environmental liabilities, particularly expenses for environmental remediation of sites Solutia never owned or operated and sites beyond the property lines of Solutia's current or former operations. The following discussion updates information regarding the significant environmental matters reflected in the Solutia-related charge. Other information with respect to such matters appears in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005.

On behalf of Pharmacia, Monsanto is a party to performing various remedial activities at the IndustriPlex site in Woburn, Massachusetts. In January 2006, the EPA is expected to publish a Record of Decision identifying additional remedial work it anticipates for the Aberjona River which is downstream of the IndustriPlex Site. It is unclear what Monsanto's responsibilities on Pharmacia's behalf will be for that additional remedial work.

On Aug. 4, 2003, the U.S. District Court for the Northern District of Alabama approved a Revised Partial Consent Decree (RPCD), pursuant to which Pharmacia and Solutia are obligated to perform PCB residential cleanup work and a remedial investigation/feasibility study of PCB contamination in Anniston, among other things. Based on Solutia's failure to perform, on March 25, 2004, Monsanto, acting on behalf of Pharmacia, entered into an arrangement with the EPA and Solutia to perform certain environmental obligations at the Anniston, Alabama, and Sauget, Illinois, sites under the RPCD and other orders where both Solutia and Pharmacia are named parties. As a part of this arrangement, Monsanto has agreed with the EPA to perform certain remediation in Anniston and Sauget until Monsanto invokes a 60-day notice of termination provision, which Monsanto has

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

not invoked. By letter dated Dec. 29, 2005, the EPA notified Pharmacia and Solutia of a demand for penalties amounting to \$1.4 million as of that date, based on alleged failure to comply with the Anniston RPCD. Monsanto believes that Pharmacia is in full compliance with the RPCD, and will contest these penalties on Pharmacia's behalf.

Guarantees: As disclosed in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005, Monsanto provides guarantees to certain banks that provide loans to Monsanto customers in Brazil. Due to the seasonal nature of Monsanto's business and increased customer participation in the loan programs, the level of customer loans with these banks and related Monsanto guarantees has increased since Aug. 31, 2005. As a result, the maximum potential amount of future payments under these guarantees was \$113 million as of Nov. 30, 2005. Based on a current assessment of credit exposure, Monsanto has recorded a liability of \$2 million related to these guarantees. Monsanto's recourse under these guarantees is limited to the customer, and it is not currently estimable.

Except as described above, there have been no significant changes to guarantees made by Monsanto since Aug. 31, 2005. Disclosures regarding these guarantees made by Monsanto can be found in Note 23 -- Commitments and Contingencies -- of the notes to the consolidated financial statements contained in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005. Disclosure regarding the guarantees Monsanto provides for certain customer loans in the United States and Brazil can be found in Note 5 -- Customer Financing Programs -- of this Form 10-Q. Information regarding Monsanto's indemnification obligations to Pharmacia under the Separation Agreement relating to Solutia's Assumed Liabilities can be found above.

NOTE 16. SEGMENT INFORMATION

Operating segments are organized primarily by similarity of products and aggregated into two reportable segments: Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and traits businesses and genetic technology platforms. The Agricultural Productivity segment consists of the crop protection products, animal agriculture businesses and lawn-and-garden herbicide products. Sales between segments were not significant. Certain selling, general and administrative expenses are allocated between segments primarily by the ratio of segment sales to total Monsanto sales, consistent with the company's historical practice. Based on the Seeds and Genomics segment's increasing contribution to total Monsanto operations, the allocation percentages were changed at the beginning of fiscal year 2006. Segment data is presented in the table that follows.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

(Dollars in millions)

Net Sales(1)

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Corn seed and traits
Soybean seed and traits
Vegetable and fruit seed(2)
All other crops seeds and traits

Total Seeds and Genomics

ROUNDUP and other glyphosate-based herbicides
All other agricultural productivity products

Total Agricultural Productivity

Total

EBIT(3)

Seeds and Genomics
Agricultural Productivity

Total

Depreciation and Amortization Expense

Seeds and Genomics
Agricultural Productivity

Total

-
- (1) Represents net sales from continuing operations.
(2) Consists of net sales from Seminis, which was acquired by Monsanto in the third quarter of fiscal year 2005. See Note 3 -- Business Combinations -- for further discussion of the Seminis acquisition.
(3) EBIT is defined as earnings (loss) before interest and taxes; see the following table for reconciliation. Earnings (loss) is intended to mean net income (loss) as presented in the Statement of Consolidated Operations under generally accepted accounting principles. EBIT is the primary operating performance measure for the two business segments.

A reconciliation of EBIT to net income (loss) for each quarter follows:

(Dollars in millions)

EBIT

Interest Expense -- Net
Income Tax Provision (Benefit) (1)

Net Income (Loss)

-
- (1) Includes the income tax provision (benefit) from continuing operations and the income tax benefit on discontinued operations.

NOTE 17. DISCONTINUED OPERATIONS

Environmental technologies businesses: In second quarter 2005, Monsanto

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

committed to a plan to sell Enviro-Chem Systems, Inc. ("Enviro-Chem" or the "environmental technologies businesses") that met the "held for sale" criteria under SFAS 144. The environmental technologies businesses provided engineering, procurement and construction management services, and sold proprietary equipment and process technologies. The environmental technologies businesses were previously reported as part of the Agricultural Productivity segment. The company determined that these businesses were no longer consistent with its strategic business goals. In August 2005, the company completed the sale of substantially all of Enviro-Chem to a new company formed by the management of the businesses and an outside investor.

In April 2001, Enviro-Chem entered into an agreement with a third party related to the engineering, design and construction of a power generation plant in Oregon. As of the date of the divestiture, the receivable related to this power plant and related fixed assets had not been collected. The title to the receivable was transferred to the buyer of Enviro-Chem, and the buyer entered into an agreement with Monsanto in August 2005 to remit the proceeds of this receivable to Monsanto upon repayment by the third party. As such, the receivable that the third party owed to Enviro-Chem has been recorded as an asset of discontinued operations as of Nov. 30, 2005, and Aug. 31, 2005. The company evaluated the carrying amount of the receivable as of Aug. 31, 2005, and

21

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED (continued)

recorded a \$4 million after-tax charge in discontinued operations to adjust the receivable to fair value based on a third-party valuation. As of Nov. 30, 2005, and Aug. 31, 2005, the miscellaneous receivable of \$10 million was recorded as an asset of discontinued operations. As of Aug. 31, 2005, this receivable had a related deferred tax asset of \$5 million recorded as an asset of discontinued operations. As of Nov. 30, 2005, this receivable had a deferred tax liability of \$4 million recorded as a liability of discontinued operations due to management's decision to include this receivable as part of the disposition for income tax purposes. Monsanto expects that it will collect the outstanding receivable balance in fiscal year 2006.

As of Aug. 31, 2005, liabilities of discontinued operations consisted of \$6 million for the resolution of a purchase price adjustment and an accrual of \$5 million for the resolution of a warranty obligation that was related to the operations of the environmental technologies businesses prior to its disposal. In first quarter 2006, Monsanto resolved and paid \$6 million for the purchase price adjustment and \$5 million for the warranty obligation.

European wheat and barley business and plant-made pharmaceuticals program: As discussed earlier in Note 4 -- Restructuring, in October 2003, Monsanto announced plans to exit the European breeding and seed business for wheat and barley and to discontinue the plant-made pharmaceuticals program. The European wheat and barley business and plant-made pharmaceuticals program were previously reported as part of the Seeds and Genomics segment. In fiscal year 2004, the sale of assets associated with the European wheat and barley business to RAGT Genetique, S.A. in Rodez, France, was finalized.

The divestiture also generated a tax loss that was recognized as a tax benefit in the United States. In first quarter 2005, Monsanto recorded a deferred tax benefit of \$106 million, \$20 million in continuing operations and the remaining \$86 million in discontinued operations. The tax benefit of \$86 million recorded in discontinued operations was related primarily to the wheat reporting unit

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

goodwill impairment loss at the date of adoption of SFAS 142 on Jan. 1, 2002, which was recorded as a cumulative effect of a change in accounting principle. See Note 4 for discussion of the \$20 million tax benefit recorded in continuing operations and Note 8 -- Income Taxes -- for further discussion of the tax benefit.

As a result of the plans to sell the three businesses discussed above, certain financial data for these businesses has been presented as discontinued operations in accordance with SFAS 144. Accordingly, for first quarter 2006 and first quarter 2005 the Statement of Consolidated Operations has been conformed to this presentation. As of Nov. 30, 2005, and Aug. 31, 2005, the Statement of Consolidated Financial Position has been conformed to this presentation. The remaining assets and liabilities of the environmental technologies businesses as of Nov. 30, 2005, and Aug. 31, 2005, follow:

	As

(Dollars in millions)	-----

Assets of Discontinued Businesses Held for Sale:	
Miscellaneous receivables	\$
Deferred tax assets	

Total Assets of Discontinued Businesses Held for Sale	\$
=====	
Liabilities of Discontinued Businesses Held for Sale:	
Current liabilities	\$

Total Liabilities of Discontinued Businesses Held for Sale	\$
=====	

The following amounts related to the environmental technologies businesses, European wheat and barley business and the plant-made pharmaceuticals program have been segregated from continuing operations and reflected as discontinued operations:

	Thre

(Dollars in millions)	-----

Net Sales	\$
Income (Loss) from Operations of Discontinued Businesses	
Income Tax Benefit	

Net Income on Discontinued Operations	\$
=====	

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

OF OPERATIONS

OVERVIEW

Background

Monsanto Company, along with its subsidiaries, is a global provider of agricultural products for farmers. We produce leading seed brands, including DEKALB, ASGROW, SEMINIS and STONEVILLE, and we develop biotechnology traits that assist farmers in controlling insects and weeds. We provide other seed companies with genetic material and biotechnology traits for their seed brands. We also manufacture ROUNDUP brand herbicides and other herbicides. Our seeds, biotechnology trait products and herbicides provide growers with solutions that improve productivity, reduce the costs of farming, and produce healthier foods for consumers and better feed for animals. We also provide lawn-and-garden herbicide products for the residential market and animal agricultural products focused on improving dairy cow productivity and swine genetics.

We manage our business in two segments: Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment consists of the global seeds and traits businesses, and genetic technology platforms. The Agricultural Productivity segment consists of our crop protection products (ROUNDUP and other glyphosate-based herbicides and selective chemistries), animal agriculture businesses and lawn-and-garden herbicide products.

In second quarter 2005, we committed to a plan to sell the environmental technologies businesses, and in fourth quarter 2005, we sold substantially all of these businesses. In fiscal year 2004, we announced plans to exit the European breeding and seed business for wheat and barley and to discontinue the plant-made pharmaceuticals program, and we sold the assets associated with our European wheat and barley business. As a result of these exit plans, financial data for these businesses have been presented as discontinued operations as outlined below. The financial statements have been recast and prepared in compliance with the provisions of Statement of Financial Accounting Standard (SFAS) No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (SFAS 144). Accordingly, for the three months ended Nov. 30, 2005, and Nov. 30, 2004, the Statement of Consolidated Operations has been conformed to this presentation. Also, under the guidance of SFAS 144, the remaining assets and liabilities of the environmental technologies businesses have been separately presented on the Condensed Statement of Consolidated Financial Position as of Nov. 30, 2005, and Aug. 31, 2005. The European wheat and barley business and the plant-made pharmaceuticals program were previously reported as part of the Seeds and Genomics segment, and the environmental technologies businesses were previously reported as part of the Agricultural Productivity segment. See Item 1 -- Note 17 -- Discontinued Operations -- for further details.

Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should be read in conjunction with Monsanto's consolidated financial statements and the accompanying notes. This Report on Form 10-Q should also be read in conjunction with Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005. Financial information for the first three months of fiscal year 2006 should not be annualized because of the seasonality of our business. The notes to the consolidated financial statements referred to throughout this MD&A are included in Part I -- Item 1 -- Financial Statements -- of this Report on Form 10-Q. Unless otherwise indicated, "Monsanto," the "company," "we," "our" and "us" are used interchangeably to refer to Monsanto Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context. Monsanto includes the operations, assets and liabilities that were previously the agricultural business of Pharmacia Corporation, which is now

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

a subsidiary of Pfizer Inc. Unless otherwise indicated, "earnings (loss) per share" and "per share" mean diluted earnings (loss) per share. Unless otherwise indicated, in MD&A, all dollar amounts are expressed in millions, except per share amounts. Unless otherwise noted, all amounts and analyses are based on continuing operations. Unless otherwise indicated, trademarks owned or licensed by Monsanto or its subsidiaries are shown in all capital letters. Unless otherwise indicated, references to "ROUNDUP herbicides" mean ROUNDUP branded herbicides, excluding all lawn-and-garden herbicides, and references to "ROUNDUP and other glyphosate-based herbicides" exclude all lawn-and-garden herbicides.

Non-GAAP Financial Measures

MD&A includes financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), as well as two other financial measures, EBIT and free cash flow, that are considered "non-GAAP financial measures." Generally, a non-GAAP financial measure is a numerical measure of a company's financial performance, financial position or cash flows that exclude (or include) amounts that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP. The

23

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

presentation of EBIT and free cash flow information is intended to supplement investors' understanding of our operating performance and liquidity. Our EBIT and free cash flow measures may not be comparable to other companies' EBIT and free cash flow measures. Furthermore, these measures are not intended to replace net income (loss), cash flows, financial position, or comprehensive income (loss), as determined in accordance with U.S. GAAP.

EBIT is defined as earnings (loss) before interest and taxes. Earnings (loss) is intended to mean net income (loss) as presented in the Statement of Consolidated Operations under GAAP. EBIT is the primary operating performance measure for our two business segments. We believe that EBIT is useful to investors and management to demonstrate the operational profitability of our segments by excluding interest and taxes, which are generally accounted for across the entire company on a consolidated basis. EBIT is also one of the measures used by Monsanto management to determine resource allocations within the company. See Note 16 -- Segment Information -- for a reconciliation of EBIT to net income (loss) for the three months ended Nov. 30, 2005, and Nov. 30, 2004.

We also provide information regarding free cash flow, an important liquidity measure for Monsanto. We define free cash flow as the total of net cash provided or required by operations and provided or required by investing activities. We believe that free cash flow is useful to investors and management as a measure of the ability of our business to generate cash. This cash can be used to meet business needs and obligations, to reinvest in the company for future growth, or to return to our shareowners through dividend payments or share repurchases. Free cash flow is also used by management as one of the performance measures in determining incentive compensation. See the "Financial Condition, Liquidity, and Capital Resources -- Cash Flow" section of MD&A for a reconciliation of free cash flow to net cash provided by operations and net cash provided (required) by investing activities on the Statement of Consolidated Cash Flows.

Executive Summary

Consolidated Operating Results -- Net sales increased \$333 million, or 31 percent, in the three-month comparison as a result of sales from the Seminis vegetable and fruit seed business that we acquired in March 2005, and increased sales of ROUNDUP herbicides in the United States, Argentina and Europe, U.S.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

corn traits and Australian cotton traits. Net income in first quarter 2006 was \$0.22 per share, compared with a net loss of \$0.15 per share in first quarter 2005.

The following factors affected the first quarter 2005 results:

- o We recorded an after-tax charge of \$181 million (\$284 million pretax), or \$0.68 per share, associated with certain liabilities in connection with the Solutia bankruptcy.
- o We recorded a deferred tax benefit of \$106 million, or \$0.40 per share, as a result of the loss incurred on the European wheat and barley business. Of this tax benefit, \$20 million was recorded in continuing operation and \$86 million was recorded in discontinued operations.

Financial Condition, Liquidity, and Capital Resources -- In first quarter 2006, net cash provided by operations was \$773 million, compared with \$769 million in the prior-year quarter. Net cash required by investing activities was \$135 million in first quarter 2006, compared with net cash provided by investing activities of \$1 million in first quarter 2005. Free cash flow was \$638 million in first quarter 2006 compared with \$770 million in the prior-year quarter. In first quarter 2005, the timing of the maturities of our short-term investments was a source of cash of \$201 million compared with no maturities in the current-year quarter. We used cash of \$53 million for ASI's acquisition of five regional seed companies in first quarter 2006. In first quarter 2005, we used cash of \$158 million for the Advanta acquisition and ASI's acquisition of Channel Bio.

Outlook -- We have evolved to a company led by its strengths in plant breeding, seeds and biotechnology traits as a means of delivering value to our customers. We aim to continually improve our products in order to maintain market leadership and to support near-term performance. We are focused on applying innovation and technology to make our farmer customers more productive and profitable by improving the ways they can produce food, fiber and feed. We use the tools of modern biology to make seeds easier to grow, to allow farmers to do more with fewer resources, and to produce healthier foods for consumers and better feed for animals. Our current research-and-development strategy and commercial priorities are focused on bringing our farmer customers second-generation traits, on delivering multiple solutions in one seed ("stacking"), and on developing new pipeline products. We aspire to bring new solutions to our customers' unmet needs, for example, crops with improved oil and protein composition or with drought tolerance. Our capabilities in

24

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

biotechnology and breeding research are generating a rich product pipeline that is expected to drive long-term growth. Our biotechnology and trait pipeline is focused on products that provide beneficial genetic traits to enhance plants' growth or to provide nutritional or other benefits to farmers, food and feed processors, or consumers. The viability of our product pipeline depends in part on the speed of regulatory approvals globally, and on continued patent and legal rights to offer our products. As a key determinant of our ability to launch new products, we have focused on aspects of the process we can control. We also continue to focus on different sales and distribution opportunities for our products.

In fiscal year 2005, we completed the acquisitions of Advanta, Seminis and Emergent and formed American Seeds, Inc., which acquired Channel Bio and NC+

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Hybrids. In first quarter 2006, ASI acquired five regional U.S. seed companies. Seminis is well positioned to capitalize on the fast-growing vegetable and fruit segment of the agriculture industry, and the acquisition expands our ability to grow. We aim to improve and to grow the Seminis business by applying our molecular breeding and marker capabilities to its library of vegetable and fruit germplasm. Further, the addition of Emergent completes a strategic cotton germplasm and traits platform modeled on our branded and licensing strategies for corn and soybeans. Over the next year, we plan to focus on accelerating the potential growth of these new businesses and executing our business plan.

ROUNDUP herbicides remain the market leader. We are focused on optimizing the supply chain and managing the costs associated with our agricultural chemistry business as that sector matures globally. The mix of our glyphosate products sold reflects the increased competitive dynamics of the marketplace.

We are required to indemnify Pharmacia for Solutia's Assumed Liabilities (defined in Note 15), to the extent that Solutia fails to pay, perform or discharge those liabilities. Prior to and following its filing for bankruptcy protection, Solutia has disclaimed responsibility for some of Solutia's Assumed Liabilities. See Note 15 for further details. Accordingly, in first quarter 2005, we recorded a pre-tax charge of \$284 million for estimated litigation and environmental costs we expect to incur in connection with Solutia's bankruptcy. The charge may not reflect all potential liabilities that we may incur in connection with Solutia's bankruptcy and does not reflect any insurance reimbursement or any recoveries we might receive through the bankruptcy process.

See the "Outlook" section of MD&A for a more detailed discussion of certain of the opportunities, challenges and risks we have identified for our business.

25

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

RESULTS OF OPERATIONS -- FIRST QUARTER FISCAL YEAR 2006

Net Sales

Gross Profit

Operating Expenses:

Selling, general and administrative expenses

Research and development expenses

Acquired in-process research and development (see Note 3)

Restructuring charges

Total Operating Expenses

Income from Operations

Interest expense

Interest income

Solutia-related expenses (see Note 15)

Other expense (income) -- net

Income (Loss) from Continuing Operations Before Income Taxes

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Income tax provision (benefit)

Income (Loss) from Continuing Operations

Discontinued Operations:

Income (loss) from operations of discontinued businesses

Income tax benefit

Income on Discontinued Operations

Net Income (Loss)

Diluted Earnings (Loss) per Share:

Income (loss) from continuing operations

Income on discontinued operations

Net Income (Loss)

Effective Tax Rate (continuing operations)

Comparison as a Percent of Net Sales:

Gross profit

Selling, general and administrative expenses

Research and development expenses (excluding acquired IPR&D)

Total operating expenses

Income (loss) from continuing operations before income taxes

Net income (loss)

The following explanations discuss the significant components of our results of operations that affected the quarter-to-quarter comparison of our first quarter income from continuing operations:

Net sales increased 31 percent in first quarter 2006 from the same quarter a year ago. Our Seeds and Genomics segment net sales improved 40 percent and our Agricultural Productivity segment net sales improved 24 percent. The following table presents the percentage changes in first quarter 2006 worldwide net sales by segment compared with the prior-year quarter, including the effect volume, price, currency and acquisitions had on these percentage changes:

	First Quarter 2006 Percentage Change in Net Sales vs. First Quarter 2005				Impact of Acquisitions
	Volume	Price	Currency	Subtotal	
Seeds and Genomics Segment	2%	8%	3%	13%	
Agricultural Productivity Segment	26%	(7)%	5%	24%	
Total Monsanto Company	16%	(1)%	4%	19%	

(1) See Note 3 -- Business Combinations -- and "Financial Condition, Liquidity, and Capital Resources" in MD&A for details of our acquisitions in fiscal years 2006 and 2005. Acquisitions are segregated in this presentation for one year from the acquisition date.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

For a more detailed discussion of the factors affecting the net sales comparison, see the "Seeds and Genomics Segment" and the "Agricultural Productivity Segment" sections.

Gross profit increased 29 percent in the three-month comparison. Total company gross profit as a percent of net sales decreased 1 percentage point to 45 percent in first quarter 2006.

- o Gross profit as a percent of sales for the Seeds and Genomics segment decreased 1 percentage point in the quarter-over-quarter comparison to 59 percent. Amortization of inventory step-up was \$11 million for the Seminis acquisition, which negatively affected gross profit as a percent of sales. An inventory step-up is a purchase accounting requirement to write-up inventory to its market value at the time the acquisition is completed. Until the acquired inventory is sold, we earn less gross profit on our sales for the acquired businesses.
- o Gross profit as a percent of sales declined 2 percentage points for the Agricultural Productivity segment to 33 percent in first quarter 2006 because of lower average net selling prices of our branded U.S. glyphosate-based herbicides due to a mix shift to our lower-priced branded products and an August 2005 price reduction for certain branded herbicides. Also, as a result of the hurricanes in August and September 2005, we experienced slightly higher cost of goods sold for U.S. ROUNDUP herbicides due to volume variances and higher conversion costs. As a percent of net sales, POSILAC gross profit declined in the three-month comparison because of increased cost of goods sold primarily driven by actions implemented to further reduce bulk powder production to better manage working capital. A favorable mix and a price increase for our U.S. acetanilide-based herbicides coupled with first quarter 2005 portfolio rationalization of other selective herbicides in Argentina somewhat offset these factors.

Operating expenses increased 30 percent, or \$120 million, in first quarter 2006 from the prior-year comparable quarter. In the three-month comparison, selling, general and administrative (SG&A) expenses increased 32 percent and research and development (R&D) expenses increased 41 percent primarily because of expenses for the businesses we acquired in 2005, largely Seminis and, to a lesser extent, ASI's acquisitions of Channel Bio and NC+ Hybrids, and Emergent. Further, in first quarter 2006, we began to expense stock options in accordance with SFAS 123R; accordingly, we recorded \$7 million in SG&A expenses and \$2 million in R&D expenses (see Note 11 -- Stock-Based Compensation). As a percent of net sales, SG&A expenses were 25 percent in both three-month periods, and R&D expenses increased 1 percentage point to 12 percent in first quarter 2006. Lastly, in first quarter 2005, we recorded charges of \$12 million related to the acquisitions of Channel Bio and Advanta for the write-off of acquired in-process R&D (IPR&D). Management believed the technological feasibility of the acquired IPR&D was not established and that the research had no alternative future uses. Accordingly, the amounts allocated to IPR&D were required to be expensed immediately under generally accepted accounting principles.

Interest expense increased \$7 million in the three-month comparison because of higher interest payments related to the 5 1/2% 2035 Senior Notes we issued in July 2005 and interest paid on commercial paper outstanding in first quarter 2006. There was no commercial paper outstanding in first quarter 2005.

Interest income increased \$5 million in the quarter-over-quarter comparison because of higher average cash balances in first quarter 2006 and interest earned on short-term investments in the United States.

In first quarter 2005, we recorded a Solutia-related charge of \$284 million

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

pretax in anticipation of certain litigation and environmental liabilities reverting to Pharmacia, and by extension, to Monsanto. This charge was based on the best estimates by our management with input from our legal and other outside advisors. Discussions between and among the various parties involved in the Solutia bankruptcy will continue for some time, and a formal reorganization plan must ultimately be affirmed by several constituencies and the bankruptcy court. We believe that this charge, based on what is known at the time of filing this report, represents the estimated discounted cost that we would expect to incur in connection with these litigation and environmental matters. However, actual costs to the company may be materially different from this estimate. See Note 15 -- Commitments and Contingencies -- for further details.

Other income -- net was \$2 million in first quarter 2006, compared with other expense -- net of \$23 million in first quarter 2005. In first quarter 2006, we recorded foreign-currency transaction gains of \$7 million compared with foreign-currency transaction losses of \$3 million in first quarter 2005. In first quarter 2005, we established a \$15 million reserve for legal proceedings (unrelated to Solutia's Assumed Liabilities) that we believed were probable and reasonably estimable as of Nov. 30, 2004.

Income tax provision was \$35 million in first quarter 2006, compared with an income tax benefit of \$104 million in the prior-year quarter. The effective tax rate decreased to 37 percent from 45 percent in first quarter 2005. First

27

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

quarter 2006 includes a charge to establish a reserve for tax exposures in Brazil. The prior-year quarter includes a tax benefit of \$20 million in continuing operations as a result of the loss incurred on the European wheat and barley business (see the discontinued operations discussion in this section and Note 8 -- Income Taxes). The first quarter 2005 effective tax rate was also affected by the \$284 million Solutia-related charge and the \$12 million nondeductible IPR&D write-off. Without these items, our effective tax rate would have been somewhat higher in first quarter 2006 compared to first quarter 2005. This increase was driven by a shift in Monsanto's projected earnings mix to higher tax rate jurisdictions, primarily the United States.

The factors above explain the change in income (loss) from continuing operations. In first quarter 2005, we recorded income on discontinued operations of \$86 million. As discussed in Note 8, the sale of the European wheat and barley business in fiscal year 2004 generated a tax loss deductible in either the United Kingdom or the United States. As of Aug. 31, 2004, a deferred tax asset had not been recorded for the tax loss incurred in the United States because of the existence of a number of uncertainties. These uncertainties diminished with the enactment of the American Jobs Creation Act of 2004 (AJCA) on Oct. 22, 2004. As a result, Monsanto recorded a deferred tax benefit of \$106 million, or \$0.40 per share, in first quarter 2005. Of this tax benefit, \$20 million was recorded in continuing operations, and the remaining \$86 million was recorded in discontinued operations. The tax benefit of \$20 million recorded in continuing operations was related to the \$69 million goodwill impairment related to our global wheat business recorded in continuing operations in fiscal year 2004. Since the goodwill impairment was recorded in continuing operations, the related tax benefit was also recorded in continuing operations. The tax benefit of \$86 million recorded in discontinued operations was primarily related to the wheat reporting unit goodwill impairment loss at the date of adoption of SFAS 142 on Jan. 1, 2002, which was recorded as a cumulative effect of a change in accounting principle. The recognition of this tax benefit in the United States effectively precludes Monsanto from claiming any U.K. benefit for the U.K. tax loss. Accordingly, the U.K. deferred tax asset of \$71 million, which had a full

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

valuation allowance against it, was written off during the quarter ended Nov. 30, 2004.

SEEDS AND GENOMICS SEGMENT

	Thre
	200
Net Sales	
Corn seed and traits	\$ 2
Soybean seed and traits	1
Vegetable and fruit seed	1
All other crops seeds and traits	
Total Net Sales	\$ 6
Gross Profit	
Corn seed and traits	\$ 1
Soybean seed and traits	1
Vegetable and fruit seed	
All other crops seeds and traits	
Total Gross Profit	\$ 3
EBIT(1)	\$

NM = Not Meaningful

- (1) EBIT is defined as earnings (loss) before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Note 16 -- Segment Information and the "Overview -- Non-GAAP Financial Measures" section of MD&A for further details.

Seeds and Genomics Financial Performance -- First Quarter Fiscal Year 2006

Net sales of corn seed and traits increased 18 percent, or \$40 million, in the three-month comparison. Higher sales of U.S. corn traits drove the increase. In first quarter 2006, our U.S. trait mix was favorable because of sales of our triple-stack product, YIELDGARD Plus with ROUNDUP READY Corn 2. In 2005, our YIELDGARD Plus with ROUNDUP READY Corn 2 product was not available for sale until second quarter. Sales of our U.S. corn traits also improved because of increased trait penetration in our branded, licensed and ASI channels, higher sales volume of branded traits due to market share gain and timing of seed shipments, and favorable ROUNDUP Rewards claim adjustments related to 2005. Our corn seed sales increased modestly in the three-month comparison. Higher corn seed sales in Mexico and Brazil were nearly offset by lower corn seed sales in South Africa.

In first quarter 2006, vegetable and fruit seed net sales of \$125 million represented nearly 20 percent of total Seed and Genomics net sales. In March 2005, we acquired Seminis Inc., the leading global vegetable and fruit seed company.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

All other crops seed and trait net sales increased 49 percent, or \$30 million, in first quarter 2006 primarily because of higher cotton trait sales in Australia. In the three-month comparison, our cotton trait sales mix consisted of a higher percentage of the BOLLGARD II with ROUNDUP READY cotton stacked offering. Planted cotton acres in Australia declined slightly in first quarter 2006 compared with first quarter 2005, but our sales volume increased in the three-month comparison because of increased trait penetration. In 2006, we expect that Australian cotton growers are using a Monsanto trait on approximately 90 percent of cotton acres planted compared with approximately 78 percent in the 2005 season.

EBIT for the Seeds and Genomics segment increased \$5 million to \$19 million in first quarter 2006. The sales increases discussed throughout this section resulted in \$104 million higher gross profit in first quarter 2006. Gross profit as a percent of sales for this segment decreased 1 percentage point in the quarter-over-quarter comparison to 59 percent primarily because of the amortization of the inventory step-up related to the Seminis acquisition of \$11 million. In the three-month comparison, increased SG&A and R&D expenses related to the 2005 acquisitions offset the gross profit improvement.

AGRICULTURAL PRODUCTIVITY SEGMENT

	Thru
	200
Net Sales	
ROUNDUP and other glyphosate-based herbicides	\$ 5
All other agricultural productivity products	2
Total Net Sales	\$ 7
Gross Profit	
ROUNDUP and other glyphosate-based herbicides	\$ 1
All other agricultural productivity products	
Total Gross Profit	\$ 2
EBIT(1)	\$

(1) EBIT is defined as earnings (loss) before interest and taxes. Interest and taxes are recorded on a total company basis. We do not record these items at the segment level. See Note 16 -- Segment Information and the "Overview -- Non-GAAP Financial Measures" section of MD&A for further details.

Agricultural Productivity Financial Performance -- First Quarter Fiscal Year 2006

Net sales of ROUNDUP and other glyphosate-based herbicides increased 26 percent, or \$114 million, in the quarter-to-quarter comparison. In the three-month comparison, sales volumes of ROUNDUP herbicides increased significantly in the United States, Argentina and Europe. The net average selling price of ROUNDUP herbicides declined primarily because of a shift in mix to our lower-priced branded herbicides in the United States coupled with U.S. and Brazilian price reductions for certain branded products in the three-month comparison. Also, the Brazilian real exchange rate favorably impacted our first quarter 2006 sales. In fiscal year 2005, the supply of generic glyphosate from China continued to grow

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

somewhat, but because of major energy and raw material shortages, it was generally supplied at higher prices. The tight supply and higher Chinese prices provided greater pricing flexibility outside of the United States to everyone in the industry. Recently, the Chinese price has softened from the peak observed earlier in 2005 to the average prices recorded over the 2003-2004 period.

In 2005, we made logistical changes that aligned inventory levels of ROUNDUP herbicides in the United States closer to market demand. We continue to optimize the supply chain to improve our working capital. As a result of these actions, the sales volume of U.S. ROUNDUP herbicides increased in first quarter 2006, even though branded glyphosate herbicide inventories in the U.S. distribution channel were at similar levels at both Nov. 30, 2005, and Nov. 30, 2004. In the three-month comparison, the average net selling price of our U.S. branded glyphosate herbicides decreased as a result of a shift of sales volumes to our lower-priced branded products, particularly ROUNDUP ORIGINAL MAX, and a price reduction for ROUNDUP WEATHERMAX and RT MASTER that occurred in August 2005.

In the three-month comparison, Argentine sales volume of ROUNDUP herbicides increased because of a change in distribution strategy and a successful October 2005 launch of the ROUNDUP ULTRAMAX brand. In Argentina, we previously sold our crop protection products primarily through distributors. In fiscal year 2004, we changed our Argentine distribution strategy to sell directly to growers. Our sales were lower in first quarter 2005 compared with first quarter 2006 primarily because Argentine distributors still had some remaining quantities of our products on hand for sale in first quarter 2005.

29

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

Sales volume of ROUNDUP herbicides increased in Europe, most notably in France, primarily because of a timing shift between first and second quarters of 2006 compared with 2005. In 2006, sales occurred earlier in France because certain customers purchased ROUNDUP herbicides prior to the implementation of an ecology tax on herbicide sales in November 2005.

Sales of ROUNDUP herbicides in Brazil decreased slightly in the quarter-over-quarter comparison. The average net selling price was lower in first quarter 2006 because we decreased the price of ROUNDUP herbicides twice after first quarter 2005 as a result of competitive conditions. The price decreases also resulted from the appreciation of the Brazilian real because the local price is tied to the U.S. dollar. Lower prices were nearly offset by the favorable effect of the Brazilian real exchange rate and a slight increase in volume.

Sales of all other agricultural productivity products increased 18 percent, or \$31 million, in the quarter-over-quarter comparison. Sales of animal agriculture products increased primarily because we increased the number of doses allocated among customers for our POSILAC product four times after first quarter 2005. See the "Outlook -- Agricultural Productivity" section of MD&A for the background of the POSILAC product allocation.

EBIT for the Agricultural Productivity segment increased \$321 million to income of \$93 million in first quarter 2006. In first quarter 2005, the largest driver of the negative EBIT was the \$284 million Solutia-related charge. Also contributing to the quarter-over-quarter EBIT improvement was higher gross profit of \$39 million resulting from the net sales increases discussed throughout this section. Gross profit as a percent of sales for the Agricultural Productivity segment declined 2 percentage points to 33 percent in first quarter 2006. See the "Results of Operations -- First Quarter Fiscal Year 2006" section of MD&A for the gross profit discussion for this segment.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Our Agreement with Scotts

In 1998, Former Monsanto entered into an agency and marketing agreement with the Scotts Miracle-Gro Company (Scotts) with respect to the lawn-and-garden herbicide business, which was transferred to us in connection with our separation from Pharmacia. See the "Agricultural Productivity Segment -- Our Agreement with Scotts" section of MD&A in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, for a detailed discussion of this agreement. Under the agreement, Scotts is obligated to pay us a \$20 million fixed fee each year for the length of the contract to defray costs associated with the lawn-and-garden herbicide business. Of the total fixed fee that was owed for the first three years of the agreement, Scotts deferred \$40 million and was contractually required to repay this amount in full, with interest. Beginning in program year 2003 (the program year is defined as October 1 to September 30), Scotts began paying these deferred amounts (\$5 million per year for both the deferred portion of the fixed fee and interest in monthly installments) plus an accelerated payment if certain earnings thresholds were achieved, starting with program year 2001. As of Aug. 31, 2005, the total amount owed by Scotts, including accrued interest, was \$44 million. In September 2005, Scotts made an accelerated payment of \$1 million, and in October 2005, Scotts elected to pay us the entire amount of the deferred payment, including accrued interest, of \$43 million. This payment is reflected in the other items line of the operating activities section on the Statement of Consolidated Cash Flows.

We are obligated to pay Scotts an annual commission based on the earnings of the lawn-and-garden herbicide business (before interest and income taxes). The amount of the commission due to Scotts varies depending on whether or not the earnings of the lawn-and-garden herbicide business exceed certain thresholds that vary by program year. The commission expense, which is not netted with any payments received from Scotts, was \$4 million in both first quarter 2006 and first quarter 2005, and is included in SG&A expenses.

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

RESTRUCTURING

Our results include restructuring activities that affected net income (loss). Restructuring charges were recorded in the Statement of Consolidated Operations as follows:

(Dollars in millions)

Restructuring Charges(1)

Loss from Continuing Operations Before Income Taxes
Income Tax Benefit

Income from Continuing Operations

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Net Income

- (1) The \$1 million of restructuring charges for the three months ended Nov. 30, 2004, was recorded in the Agricultural Productivity segment.

Fiscal Year 2004 Restructuring Plan: In October 2003, we announced plans to continue to reduce costs primarily associated with our agricultural chemistry business as that sector matures globally. These plans included: (1) reducing costs associated with our ROUNDUP herbicide business, (2) exiting the European breeding and seed business for wheat and barley, and (3) discontinuing the plant-made pharmaceuticals program. Additionally, the approved plan included a \$69 million impairment of goodwill in the global wheat business. Total restructuring charges related to these actions were \$165 million pretax (\$105 million aftertax) in fiscal year 2004 and \$6 million pretax in fiscal year 2005.

In first quarter 2005, we recorded restructuring charges of \$1 million pretax related to workforce reductions. Also, in first quarter 2005, we recorded a deferred tax benefit of \$106 million, of which \$20 million was recorded in continuing operations, and the remaining \$86 million was recorded in discontinued operations. The \$20 million tax benefit recorded in continuing operations was related to the impairment of goodwill in the global wheat business as part of the fiscal year 2004 restructuring plan. As such, the benefit amount recorded in continuing operations is reflected in the table above. See Note 17 -- Discontinued Operations -- and the "Results of Operations" section of MD&A for a further discussion of the \$86 million tax benefit recorded in discontinued operations.

The actions relating to this restructuring plan resulted in after-tax savings of approximately \$85 million and \$40 million in fiscal years 2005 and 2004, respectively, and they are expected to produce after-tax savings of approximately \$85 million to \$90 million in fiscal year 2006, with continuing savings thereafter. We expect that these actions will lower our costs, primarily SG&A, as a percent of sales.

31

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES

Working Capital and Financial Condition

	As of Nov.	
(Dollars in millions, except current ratio)	2005	
Cash and cash equivalents	\$ 1,006	\$
Short-term investments	168	
Trade receivables -- net	1,413	
Inventories	1,890	
Other current assets (1)	963	
Total Current Assets	\$ 5,440	\$

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Short-term debt	\$ 155	\$
Accounts payable	370	
Accrued liabilities (2)	2,301	
<hr/>		
Total Current Liabilities	\$ 2,826	\$
<hr/>		
Working Capital (3)	\$ 2,614	\$
Current Ratio (3)	1.92:1	2
<hr/>		

- (1) Includes miscellaneous receivables, current deferred tax assets, assets of discontinued operations and other current assets.
- (2) Includes income taxes payable, accrued compensation and benefits, accrued marketing programs, deferred revenues, grower accruals, contingent purchase price -- Seminis (only as of Nov. 30, 2005), liabilities of discontinued operations and miscellaneous short-term accruals.
- (3) Working capital is total current assets less total current liabilities; current ratio represents total current assets divided by total current liabilities.

Nov. 30, 2005, compared with Aug. 31, 2005: Working capital increased \$129 million between Aug. 31, 2005, and Nov. 30, 2005, because of the following factors:

- o Cash and cash equivalents increased \$481 million between the respective periods. See the "Cash Flow" section in this section of MD&A for further details of this increase.
- o Inventories increased \$226 million between the respective periods primarily because the seasonality of our U.S. corn and soybean seed business in which the fall harvest of seed products occurs in first quarter of the fiscal year resulting in a higher inventory balance as of Nov. 30, 2005.
- o Other current assets increased \$131 million primarily because of an increase in deferred tax assets. We reclassified \$138 million of non-current deferred tax assets on net operating losses to current deferred tax assets because we expect it will be utilized in fiscal year 2006.
- o Short-term debt decreased \$127 million in the three-month comparison because of lower technical overdrafts and lower short-term borrowings. See the "Capital Resources and Liquidity" section within this section of MD&A for the explanation.

These increases to working capital between Aug. 31, 2005, and Nov. 30, 2005, were offset by \$793 million of higher accrued liabilities as of Nov. 30, 2005. Our deferred revenue balance increased from \$43 million as of Aug. 31, 2005, to \$703 million as of Nov. 30, 2005, due to U.S. customer prepayments in first quarter 2006. Also, we recorded a liability of \$125 million as of Nov. 30, 2005, for a payment related to the Seminis acquisition (see the discussion in "Capital Resources and Liquidity" of this section).

Nov. 30, 2005, compared with Nov. 30, 2004: Working capital decreased \$355 million in the comparison between Nov. 30, 2005, and Nov. 30, 2004. The following factors decreased working capital as of Nov. 30, 2005, compared with Nov. 30, 2004:

- o Cash and cash equivalents decreased \$547 million between the respective periods. As presented on the Statement of Consolidated Cash Flows, the net increase in cash and cash equivalents was \$481 million in first quarter 2006 compared with \$516 million in first quarter

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

2005. The cash and cash equivalents balance was lower as of Aug. 31, 2005, compared with Aug. 31, 2004, by \$512 million primarily because of payments for acquisitions in 2005.

32

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

- o Accrued liabilities increased \$509 million primarily because customer prepayments were approximately \$140 million higher in first quarter 2006 compared with first quarter 2005. As discussed previously in this section, we recorded a \$125 million liability related to the Seminis acquisition as of Nov. 30, 2005. Also, accrued rebates increased between the respective periods primarily because of new U.S. marketing programs introduced in fourth quarter 2005. Lastly, accrued liabilities related to the Seminis and Emergent acquisitions were approximately \$95 million as of Nov. 30, 2005.

The working capital decreases were offset by an increase in inventory of \$438 million between the respective periods primarily because of inventory related to the acquisitions of Seminis and, to a lesser extent, Emergent, which was approximately \$435 million as of Nov. 30, 2005.

Customer Financing Programs: We refer certain of our interested U.S. customers to a third-party specialty lender that makes loans directly to our customers. In April 2002, we established this revolving financing program of up to \$500 million, which allows certain U.S. customers to finance their product purchases, royalties and licensing fee obligations. The funding availability may be less than \$500 million if certain program requirements are not met. It also allows us to reduce our reliance on commercial paper borrowings. We received \$18 million in first quarter 2006 and \$60 million in first quarter 2005 from the proceeds of loans made to our customers through this financing program. These proceeds are included in the net cash provided by operations in the Statement of Consolidated Cash Flows. We originate these customer loans on behalf of the third-party specialty lender, a special purpose entity (SPE) that we consolidate, using our credit and other underwriting guidelines approved by the lender. We service the loans and provide a first-loss guarantee of up to \$100 million. Following origination, the lender transfers the loans to multi-seller commercial paper conduits through a nonconsolidated qualifying special purpose entity (QSPE). We have no ownership interest in the lender, in the QSPE, or in the loans. We account for this transaction as a sale, in accordance with SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishment of Liabilities.

As of Nov. 30, 2005, and Aug. 31, 2005, the customer loans held by the QSPE and the QSPE's liability to the conduits were \$119 million and \$171 million, respectively. The lender or the conduits may restrict or discontinue the facility at any time. If the facility were to be terminated, the existing loans would be collected by the QSPE over their remaining terms (generally 12 months or less), and we would revert to our past practice of providing these customers with direct credit purchase terms. Our servicing fee revenues collected and earned from the program were not significant during the first quarters of 2006 and 2005. As of Nov 30, 2005, and Aug. 31, 2005, our recorded guarantee liability was less than \$1 million, primarily based on our historical collection experience with these customers and a current assessment of credit exposure. Adverse changes in the actual loss rate would increase the liability.

In January 2003, the FASB issued FASB Interpretation No. 46, Consolidation of Variable Interest Entities (FIN 46), and amended it by issuing FIN 46R in December 2003. The SPE is included in our consolidated financial statements. Because QSPEs are excluded from the scope of FIN 46R and we do not have the

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

unilateral right to liquidate the QSPE, this interpretation does not have an effect on our accounting for the U.S. customer financing program.

In November 2004, we entered into an agreement with a lender to establish a program to provide financing of up to \$40 million for selected customers in Brazil. The agreement as amended in May 2005 qualifies for sales treatment under SFAS 140. Proceeds from the transfer of the receivables subsequent to the May 2005 amendment are included in net cash provided by operations in the Statement of Consolidated Cash Flows. In first quarter 2006, the total amount of customer receivables transferred through the program was \$18 million. The amount of loans outstanding was \$37 million and \$22 million as of Nov. 30, 2005, and Aug. 31, 2005, respectively. We provide a full guarantee of the loans in the event of customer default. The liability for the guarantee is recorded at an amount that approximates fair value and is primarily based on our historical collection experience with customers that participate in the program. The guarantee liability recorded by Monsanto was \$1 million as of Nov. 30, 2005, and less than \$1 million as of Aug. 31, 2005. If performance is required under the guarantee, we may retain amounts that are subsequently collected from customers.

33

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

Cash Flow

(Dollars in millions)

Net Cash Provided by Operations

Net Cash Provided (Required) by Investing Activities

Free Cash Flow(1)

Net Cash Required by Financing Activities

Net Increase in Cash and Cash Equivalents

Cash and Cash Equivalents at Beginning of Period

Cash and Cash Equivalents at End of Period

(1) Free cash flow represents the total of net cash provided or required by operations and provided or required by investing activities (see the "Non-GAAP Financial Measures" section in MD&A for a further discussion).

Cash provided by operations improved \$4 million in the quarter-over-quarter comparison. The change in accounts payable and accrued liabilities was a use of cash of \$127 million in first quarter 2006 compared with a source of cash of \$6 million in the prior-year quarter. The higher use of cash for these items in first quarter 2006 was mainly the result of higher employee incentive payouts as a result of the plan change to a fiscal year basis. Our incentive accrual as of Aug. 31, 2004, which was paid in first quarter 2005, represented an eight-month incentive period. Our incentive plan was changed in fiscal year 2005 to match our change in fiscal year. The incentive accrual as of Aug. 31, 2005, was based on a 12-month incentive period, and was also higher because financial performance improved in 2005 compared with 2004. Further, the timing of U.S. income tax accruals and payments contributed to the increased use of cash in the three-month comparison. In first quarter 2006, other items were a source of cash

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

of \$114 million, which the largest item was the \$43 million payment we received from Scotts (see the "Agricultural Productivity Segment" section of MD&A).

Cash required by investing activities was \$135 million in first quarter 2006 compared with cash provided by investing activities of \$1 million in first quarter 2005. In first quarter 2005, the timing of the maturities of our short-term investments was a source of cash of \$201 million compared with no maturities in the current-year quarter. We used cash of \$53 million for ASI's acquisition of five regional seed companies in first quarter 2006. In first quarter 2005, we used cash of \$158 million for the Channel Bio and Advanta acquisitions. These acquisitions are explained in more detail in the "Capital Resources and Liquidity" section below. Lastly, our capital expenditures were 44 percent, or \$17 million, higher in first quarter 2006 compared with the prior-year quarter. This increase was primarily driven by expansion of seed production facilities for corn and cotton as well as projects related to R&D. We expect fiscal 2006 capital expenditures to be in the range of \$350 million compared with fiscal year 2005 capital spending of \$281 million.

The amount of cash required by financing activities decreased \$97 million to \$157 million in first quarter 2006. The net change in short-term financing required cash of \$122 million in first quarter 2006 compared with \$22 million in the prior-year quarter. Cash required for long-term debt reductions was \$26 million in first quarter 2006 compared with \$208 million in first quarter 2005. Certain medium-term notes matured in 2005. On Oct. 25, 2005, our board of directors authorized the purchase of up to \$800 million of the company's stock over a four-year period; no shares were repurchased under this plan in first quarter 2006. In first quarter 2005, treasury stock purchases required cash of \$35 million under the \$500 million share repurchase program, which was completed in July 2005. Stock option exercises provided \$27 million of cash in first quarter 2006 compared with \$45 million in the prior-year quarter. Dividend payments increased 21 percent, or \$8 million, in first quarter 2006. In first quarter 2005, we paid a dividend of 14.5 cents per share compared with 17 cents per share in first quarter 2006.

Capital Resources and Liquidity

	As of Nov. 30,	
(Dollars in millions, except debt-to-capital ratio)	2005	2004
Short-Term Debt	\$ 155	\$ 239
Long-Term Debt	1,445	1,070
Total Shareowners' Equity	5,754	5,386
Debt-to-Capital Ratio	22%	20%

Total debt outstanding decreased \$140 million between Aug. 31, 2005, and Nov. 30, 2005, primarily because of lower technical overdrafts and lower short-term borrowings. The technical overdraft balance was higher as of Aug. 31, 2005,

because of the timing of U.S. market funding payments, which occurred in August 2005. Also, commercial paper outstanding decreased from \$43 million as of Aug. 31, 2005, to zero as of Nov. 30, 2005.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

2006 Acquisitions: In September 2005, our American Seeds, Inc. (ASI) subsidiary acquired five regional U.S. seed companies in separate transactions for an aggregate purchase price of \$53 million (net of cash acquired), inclusive of transaction costs of \$2 million. Four of the five companies acquired are the shareowners of the CORE Group, an association of family-based seed companies that serve farmers throughout the Corn Belt, which primarily encompasses several states in the north central plains region. Those four companies are Fontanelle Hybrids, Inc., Trelay Seed Company, Stone Seed Company, and Stewart Seeds, Inc. (collectively, "the CORE Group"). In the fifth transaction, ASI acquired Specialty Hybrids, Inc., a company serving the Eastern Corn Belt. These acquisitions are expected to further bolster ASI's ability to directly serve farmer-customers with a technology-rich, locally-oriented business model. The transactions were completed on Sept. 1, 2005, from which time the results of these acquisitions were included in the our consolidated financial statements. For all fiscal year 2006 acquisitions, the business operations of the acquired entities were included in the Seeds and Genomics segment. See Note 3 -- Business Combinations for the preliminary purchase price allocations as of Nov. 30, 2005.

2005 Acquisitions: In first quarter 2005, we acquired the canola seed businesses of Advanta Seeds from Advanta B.V., including the ADVANTA SEEDS brand in Canada and the INTERSTATE seed brand in the United States, for \$52 million in cash (net of cash acquired), inclusive of transaction costs of \$2 million. The transaction was completed on Sept. 8, 2004, from which time the operating results of this acquisition were included in our consolidated financial statements.

In November 2004, ASI acquired Channel Bio Corp. for \$104 million in cash (net of cash acquired) and \$15 million in liabilities paid in second quarter 2005. In third quarter 2005, ASI, through its Channel Bio subsidiary, acquired NC+ Hybrids, Inc. for \$40 million in cash (net of cash acquired). In addition to these purchase price amounts, ASI paid transaction costs of \$4 million for these acquisitions. Channel Bio and NC+ Hybrids are U.S. seed companies that sell, market and distribute primarily corn and soybean seeds. The Channel Bio transaction was completed on Nov. 15, 2004, from which time the operating results of this acquisition were included in our consolidated financial statements. The NC+ Hybrids transaction was completed on March 1, 2005, from which time the operating results of this acquisition were included in our consolidated financial statements.

In third quarter 2005, we acquired Seminis for \$1.0 billion in cash (net of cash acquired), inclusive of transaction costs of \$23 million, and we paid \$495 million for repayment of its outstanding debt. The acquisition was completed on March 23, 2005, from which time the operating results of this acquisition were included in our consolidated financial statements. Marinet Investments, LLC, which prior to the closing was a holder of co-investment rights in Seminis, elected to reduce the cash payment to which it was entitled upon completion of the transaction by \$50 million in exchange for a contingent payment of up to \$125 million based on the achievement of certain cumulative net sales targets over the 36-month period ending Sept. 30, 2007, or certain other factors. The cash portion of the acquisition was funded with cash on hand plus commercial paper borrowings of \$600 million issued in March 2005. Prior to the closing of the transaction, Seminis initiated a tender offer to redeem all of its outstanding 10 1/4% Senior Subordinated Notes. Commercial paper borrowings were also issued in April 2005 to fund the payments pursuant to the tender offer, which totaled approximately \$390 million.

In order to enhance connections among Monsanto and Seminis employees, including the sharing of technology advancements, we are finalizing plans to integrate certain support services of Seminis with our other businesses. In conjunction with this integration, in September 2005, Monsanto and the chief executive officer of Seminis agreed that he would assist in the integration and resign by Dec. 31, 2005. As a result, Monsanto determined that the timing of the

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

contingent payment discussed above has been accelerated and will be payable in second quarter 2006. A liability has been recorded as of Nov. 30, 2005, resulting in additional purchase price and goodwill of \$125 million.

In third quarter 2005, we acquired Emergent Genetics, Inc. and Emergent Genetics India Ltd. (collectively, "Emergent") for \$305 million (net of cash acquired), inclusive of transaction costs of \$8 million. The transaction was completed on April 5, 2005, from which time the operating results of this acquisition were included in our consolidated financial statements. The cash portion of the acquisition was funded with \$284 million of commercial paper borrowings issued in April 2005. We also assumed debt of \$16 million.

For all fiscal year 2005 acquisitions described above, the business operations of the acquired entities were included in the Seeds and Genomics segment. As of the acquisition dates, we began to assess and formulate plans to integrate or restructure the acquired entities. These activities are accounted for in accordance with EITF Issue No. 95-3, Recognition of Liabilities in Connection

35

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

with a Purchase Business Combination, and primarily include the potential closure of facilities, the abandonment or redeployment of equipment, and employee terminations or relocations. In first quarter 2006, we finalized plans to integrate or restructure certain activities of Seminis and the Emergent India business. As a result, asset fair values were reduced by \$2 million, and additional liabilities of \$14 million were recorded, resulting in additional goodwill of \$16 million. The plans for Seminis and the Emergent India business include employee terminations and relocations, exiting certain product lines and facility closures. As of Nov. 30, 2005, estimated integration costs of \$21 million have been recognized as current liabilities in the purchase price allocations, and \$3 million has been charged against the liabilities, primarily related to payments for employee terminations and relocations.

Contingent Liabilities Relating to Solutia Inc. (Off-Balance Sheet Arrangement)

There are no material changes related to our off-balance sheet arrangement relating to Solutia from the disclosure in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005. See Note 15 -- Commitments and Contingencies under the subheading "Solutia Inc." for further information regarding Solutia's Assumed Liabilities, the charge taken in connection with Solutia's Assumed Liabilities, and an agreement in principle which we have reached with certain other parties in Solutia's bankruptcy proceeding. Also see Part II -- Item 1 -- Legal Proceedings and Item 5 -- Relationships Among Monsanto Company, Pharmacia Corporation, Pfizer Inc. and Solutia Inc. for further information.

OUTLOOK

Focused Strategy

Monsanto has established leadership in agricultural markets by applying advanced technology to develop high-value products ahead of its competitors, and by reinforcing strong brands and customer relationships. We aim to continually improve our products in order to maintain market leadership and to support near-term performance. Our capabilities in plant breeding and biotechnology research are generating a rich product pipeline that is expected to drive long-term growth. We believe that our focused approach to our business and the

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

value we bring to our customers will allow us to maintain an industry leadership position in a highly competitive environment.

We have evolved to a company led by its strengths in seeds and biotechnology traits as a means of delivering solutions to our customers. We also remain the leading manufacturer of the best-selling herbicide brand, ROUNDUP, and maintain a very strong manufacturing cost position. We will focus geographically on our top agricultural markets, where we can bring together a broad complement of our products and technologies, while pursuing ways to best participate in other markets. We have accordingly adopted different business models for different markets. These actions allow us to diversify our exposure to risk from changes in the marketplace.

Our financial strategy will continue to emphasize both earnings and cash flow. We believe that Monsanto is positioned to sustain earnings growth and strong cash flow. We remain committed to returning value to shareowners through vehicles such as investments that grow and expand the business, an increased dividend rate and share repurchases. We have recently used our cash position for strategic acquisitions and technology investments, and we have used a combination of cash and debt to fund our 2005 acquisitions. We will continue to evaluate technology arrangements that have the potential to increase the efficiency and effectiveness of our R&D efforts, and acquisition opportunities that meet our strategic needs, although we have no current plans to pursue any major acquisitions.

We have taken decisive steps to address key risks in our business position, which include reducing costs in our agricultural chemistry business and pursuing the evolution of our business to an emphasis on seeds and traits. We remain focused on cost and cash management, both to support the progress we have made in managing our investment in working capital -- in particular, receivables and inventories -- and to realize the full earnings potential of our businesses. We will continue to seek additional external financing opportunities for our customers.

We have taken steps to reduce risk and stabilize our business position in Latin America. We continue to monitor the business environment and the related impact on our working capital in Latin American countries, particularly Brazil and Argentina. Brazil experienced drought conditions in fiscal years 2004 and 2005 in some regions, including the regions where we have been focusing our point-of-delivery payment system collection efforts. Also, the combination of lower commodity prices and the appreciation of the Brazilian real affected some of our customers' liquidity in several other Brazilian regions during fiscal

year 2005, which we expect to continue in 2006. We took actions to mitigate these credit risks in 2005 and will continue to carefully monitor our Brazilian trade receivables in 2006.

Seeds and Genomics

Monsanto has built a leading global position in seeds. We continue to make improvements in our base seed business. Advanced breeding techniques combined with production practices and plant capital investments have significantly improved germplasm quality, yields and cost. The performance of Monsanto germplasm is reflected in market-share gains for both our branded and licensed seed businesses. We also use our genetic material to develop new varieties for other seed companies' brands. Outstanding seed quality and leading germplasm provide a vehicle for delivering biotechnology seed traits such as herbicide

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

tolerance and insect protection. Biotechnology traits offer growers several benefits: lower costs, greater convenience and flexibility, higher yields, and the ability to adopt environmentally responsible practices such as conservation tillage and reduced pesticide use.

As part of this seed and technology-based strategic initiative, we are focusing on projects that we believe have the best commercial potential. To date, our research and marketing have focused on crops grown on significant acreage: corn, cotton and oilseeds, which include soybeans and canola. The acquisition of Seminis will broaden our research and marketing focus to other vegetable and fruit crops. We invest more than 85 percent of our R&D in the areas of seeds, genomics and biotechnology. These are the fastest-growing segments of the agriculture industry. By shifting our focus to create value for farmers in seeds and traits, we have set Monsanto on a path of sustainable growth. We expect increasing gross profit from seeds and traits to more than offset a declining contribution from agricultural chemicals. At the same time, we expect to continue to reduce seed production costs through higher yields on seed production acres and careful management of our seed product portfolio.

Key near-term growth opportunities in our seeds and traits include:

- o Continued growth in Monsanto's branded and licensed seed market shares, through acquisitions, successful breeding of high-performance germplasm and continuous improvement in the quality of our seeds;
- o Continued growth in licensing of seed germplasm and biotechnology traits to other seed companies through our Holden's/Corn States business and Cotton States business;
- o Expansion of existing traits, especially in corn, and stacking of additional traits in current biotechnology products;
- o Ability to have flexibility to price our traits in line with the value growers have experienced and expect to continue to experience from our traits;
- o Commercialization of second-generation traits, such as BOLLGARD II cotton and ROUNDUP READY Flex cotton; and
- o Improve and grow the Seminis vegetable and fruit seed business by applying our molecular breeding and marker capabilities to Seminis' library of germplasm.

In first quarter 2005, we formed ASI, a holding company established to support regional seed businesses with capital, genetics and technology investments. ASI intends to continue investing in independent seed businesses and to operate them autonomously as subsidiaries. These investments will allow the operating companies of ASI to more rapidly connect their customers to significant innovations in genetics-based breeding and other new technologies while continuing to operate autonomously and locally, providing service to their customers and building value of their brands. Within our U.S. business, we now have three approaches to the market, each serving unique customers in unique ways: we are selling our branded DEKALB and ASGROW seeds through the distribution channel; we are licensing to more than 250 regional seed companies through our Holden's/Corn States business; and with the addition of ASI, we are now selling directly to farmers in localized markets. ASI completed the acquisition of Channel Bio in first quarter 2005 and the acquisition of NC+ Hybrids in third quarter 2005. In September 2005, ASI acquired five companies that collectively represented approximately 1 percent of the U.S. corn seed market.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

In third quarter 2005, we completed the acquisition of Seminis, the global leader in the vegetable and fruit seed industry. Seminis continues to operate as a wholly owned subsidiary of Monsanto. Other than corn seed, oilseeds and cotton seed, vegetable seeds have the best prospect for consistent growth at high margins. Similar to Monsanto, Seminis has captured a leading position in its respective global markets, and has done so by focusing on molecular breeding and the value it creates for the farmer. From a technology perspective, we intend to continue on the path taken by Seminis for its business, which is to focus on developing products via advanced molecular breeding techniques, and to leverage our research on the seed breeding side for Seminis. We believe Seminis is an attractive investment for us because of its market leadership, innovation and financial growth. As discussed in the "Financial Condition, Liquidity, and Capital Resources" section of MD&A, we are integrating certain support services of Seminis with our other businesses. We finalized plans to integrate or restructure certain activities of Seminis and recorded a liability in first quarter 2006, which was considered part of the purchase price allocation.

In third quarter 2005, we completed the acquisition of Emergent, a cotton seed business, which we are integrating into our cotton traits business. Through the Emergent brands, we will have a branded presence in cotton as we do in corn and soybeans. Emergent will join a foundation cotton seed company called Cotton States that we created in the last three years. We will use the same model that we adopted in corn and soybeans, and we will be broadly licensing both our biotech traits and our germplasm to other companies. The decision to purchase Emergent is key to the future of our cotton business, core to accelerating the value of our new second-generation cotton traits, and complementary to the introduction of our new Cotton States foundation seed business. We expect growth to come from the combination of improved breeding and continued growth of biotech traits, particularly stacked and second-generation traits.

We can achieve continued growth through stacking and increased penetration of traits in approved markets. Trait stacking is a key growth driver in our seeds and traits business because it allows Monsanto to earn a greater share of the farmer's expenditures on each acre. Our past successes provide a significant competitive advantage in delivering stacked-trait products and improved, second-generation traits. During the past three years, stacked-trait cotton overtook single-trait cotton products in Monsanto's product mix. We are seeing the same trend in our corn seed business, where higher-value, stacked-trait products represent a growing share of total seed sales.

We have completed the regulatory approval processes in the United States, Japan and Canada for YIELDGARD Plus with ROUNDUP READY Corn 2, Monsanto's three-way stacked product that includes the YIELDGARD Corn Borer, YIELDGARD Rootworm and ROUNDUP READY Corn 2 biotech traits. YIELDGARD Plus with ROUNDUP READY Corn 2 hybrids were available for sale and planting in limited quantities in fiscal year 2005 with broader product availability in fiscal year 2006 in the United States. Monsanto corn products designed to be tolerant to the active ingredient in ROUNDUP herbicides are currently marketed as ROUNDUP READY Corn 2 in the United States.

In January 2006, the U.S. Department of Agriculture granted deregulated status for our MON88017 -- second generation product combining our rootworm and ROUNDUP READY Corn 2 trait technologies in a single event -- and MON88017 stacked with YIELDGARD Corn Borer. The EPA and FDA have also completed their reviews of MON88017. We are seeking the necessary regulatory clearances for MON88017 and MON88017 stacked with YIELDGARD Corn Borer on the U.S. state level and approvals in countries that are major importers of U.S. corn. The commercial launch timing of these products has not been announced.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

We are working toward developing products to generate long-term growth. We believe that our strategic head start in first- and second-generation input traits will give us a leadership position in developing output traits that provide consumer benefits and create value for the food industry. We are working to achieve greater acceptance and to secure additional approvals for our existing biotechnology products globally, and toward the development and timely commercialization of additional products in our pipeline. We are prioritizing our efforts to gain approvals for biotechnology crops, and while we continue to gain new approvals in global markets, we are pursuing strategies for growth even with delays in some global regulatory approvals.

The Brazilian government passed measures legalizing the planting and harvest of ROUNDUP READY soybeans in Brazil for our 2004 and 2005 fiscal years. A grain-based payment system was successfully launched in fiscal year 2004. In March 2005, Brazil's President signed a biosafety bill into law that established a regulatory process for the approval of biotech crops. The implementation of our point-of-delivery, grain-based payment system in fiscal year 2004 laid the groundwork for ensuring that we capture value on biotech crops grown in Brazil. The legalization of biotechnology in Brazil should make our system more effective and allow Brazil to be a greater contributor to revenue in seeds and traits in the near term. Most grain handlers in Brazil have enrolled or are expected to enroll in this grain-based payment system for the 2006 harvest. Many

38

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

of the southern states have already enrolled as part of a two-year contract, entered into starting with the 2005 harvest. The largest grain exporters have accepted this contract and have implemented the agreement for the past two seasons. Compliance with the system from the 2005 and 2004 harvest was estimated to be above 98 percent. It is likely that court rulings on our Brazilian patents from these non-complying cases, or new cases, will occur in fiscal year 2006 or 2007. As ROUNDUP READY soybeans have now been fully approved in Brazil, a limited amount of certified seed containing the ROUNDUP READY gene was sold in 2005, in addition to continuing with the grain-based payment system on saved and replanted seed.

A similar grain-based system has been established for Paraguay; it was successfully operated in the 2005 harvest and is expected to be operated for the 2006 harvest. As Paraguay has only five million acres of soybean production, it is expected to be a modest contributor to earnings in 2006. Efforts continue to develop systems in Argentina and Uruguay. It is likely that court cases in Europe will be required to determine the applicability of patent rights for ROUNDUP READY soybeans grown in Argentina and exported to Europe. The first two of these cases have been filed, and may take two or more years to be completed. It is not certain that payments on ROUNDUP READY soybeans will be profitable in these Latin American countries.

Crop import restrictions in some key markets, most notably the European Union, reduce potential expansion of current and future biotechnology crops in the United States and other markets where they are approved. However, the development of effective systems to enable farmers growing crops in the United States to sell into elevator systems that do not export to the EU is mitigating the effect of these restrictions. Additionally, Monsanto is pursuing approvals to enable the importation of corn and processed corn products that contain the ROUNDUP READY and YIELDGARD Rootworm traits into the EU, including those traits as a part of various stacked-trait combinations, and has received approval from the EU for human consumption, and the import, processing and use in animal feed, of ROUNDUP READY Corn 2.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

We are committed to addressing the concerns raised by consumers and by public interest groups regarding agricultural and food products developed through biotechnology. We also continue to address concerns about the adventitious or certain unintended trace presence of biotechnology materials in seed, grain or feed and food products by seeking sound, science-based rules and regulations that clarify and allow for trace amounts, and providing industry leadership to establish the highest standards of purity reasonably achievable and to establish global standards for quality. We are also working with the seed industry to develop strategies on production interventions that may reduce the likelihood of adventitious presence.

Agricultural Productivity

In recent years, we have seen reduced revenues and earnings from ROUNDUP herbicides, which reflect both the overall decline in the agricultural chemicals market and the expiration of U.S. patent protection for the active ingredient in ROUNDUP products in 2000. By aligning our infrastructure and costs with our expectations for the glyphosate herbicide market, however, we believe the ROUNDUP business can continue to be a significant and sustainable source of cash and income generation for Monsanto, even in the face of increased competition. In postpatent markets around the world, ROUNDUP herbicides have maintained a leading market position and a price premium compared with generics.

We will continue to support the market leadership of ROUNDUP herbicides with product innovations, superior customer service and logistics, low-cost manufacturing, further expansion of ROUNDUP READY crops, and the ROUNDUP Rewards program. ROUNDUP Rewards offers added protection and reduced risk program elements for farmers who use certain Monsanto technologies and agricultural herbicides. Further penetration of ROUNDUP READY crops also enhances the market position of ROUNDUP herbicides as a brand-name product that farmers trust to avoid the risk of crop injury in over-the-top use on these crops.

Hurricanes -- Katrina and Rita -- seriously disrupted the supply of petrochemical feedstocks and natural gas in the Gulf Coast region of the United States in August and September 2005. The result has been dramatic price escalation for certain raw materials and energy required for glyphosate production. We continue to monitor the effect of changes in petroleum-based products and natural gas prices on our raw materials. Although these conditions are not expected to impact our long-term results of operations, they could have a material adverse affect on our 2006 results of operations as our suppliers pass along a portion of their higher raw material costs to us.

We have several patents on our glyphosate formulations and manufacturing processes in the United States and in other countries. We continue to differentiate ROUNDUP herbicides with innovations using proprietary technology.

39

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

We also provide more concentrated formulations that provide greater convenience for farmers while reducing production and logistics costs. We offer a variety of products to meet farmers' needs.

In the United States, Monsanto maintains strong distribution relationships and a unique bulk tank system to support retailers. Monsanto remains the primary global producer of glyphosate, the active ingredient in ROUNDUP herbicides, with agreements to supply glyphosate to many of our competitors. Our high volume combined with patented process technology allows us to maintain low unit costs. We also achieved reductions in working capital by decreasing distribution

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

channel inventory to optimize our working capital and adjust to current market conditions. ROUNDUP herbicides distribution channel inventories in the United States have declined significantly over the last several years. In 2006, we expect our U.S. branded herbicide sales to correlate with the application of ROUNDUP herbicides on the farm and with our share of the overall market.

Like most other selective herbicides, Monsanto's selective herbicides face declining markets and increasing competitive pressures, but they continue to support our ability to offer fully integrated crop-protection solutions, particularly in ROUNDUP READY corn. While rapid penetration of ROUNDUP READY corn in the United States has also had a negative effect on sales of Monsanto's selective corn herbicides, gross profit from the ROUNDUP READY trait and from the ROUNDUP herbicides used on these acres are significantly higher than the gross profit on the lost selective herbicide sales.

Our lawn-and-garden herbicide products remain a strong cash generator and support Monsanto's brand equity in the marketplace.

Another key product in our Agricultural Productivity segment is POSILAC bovine somatotropin, which improves dairy cow productivity. The active ingredient for POSILAC is manufactured at our plant in Augusta, Georgia, and in Austria by Sandoz GmbH. Sandoz also manufactures the finished dose formulation of POSILAC. In second quarter 2005, we applied for U.S. FDA approval for finished dose formulation at our Augusta facility. Sandoz has implemented corrections and improvements at its facility in response to issues raised by the FDA during and following a November 2003 inspection of Sandoz's facility and further identified in a March 2004 FDA warning letter to Sandoz. Sandoz is currently awaiting reinspection and final resolution of FDA concerns. In second quarter 2004, we notified our customers that supplies of POSILAC would be limited because of a combination of factors, including the time needed for Sandoz to complete corrections and improvements at its facility in cooperation with the FDA. The reduction in finished doses of POSILAC available for sale has required us to allocate available supplies. Three times in 2005 and again in first quarter 2006, we were able to increase the number of finished doses allocated among our customers, but expect the supply of finished doses of POSILAC to continue to be limited through most of calendar year 2006. The allocation is expected to hinder POSILAC sales growth for as long as it continues. The allocation is unrelated to our level of inventory of bulk powder (active ingredient). We continue to reduce production of bulk powder while continuing to convert existing bulk powder inventory into finished doses, both of which have reduced our overall bulk powder inventory.

Recently, Monsanto and Sandoz have been negotiating changes to the current contract and, in December 2005, Sandoz delivered a notice of termination to Monsanto, which had an effective date of Dec. 31, 2008. By contract, either Monsanto or Sandoz may terminate with a two-year or three-year notice, respectively, without cause. Negotiations between Monsanto and Sandoz are expected to continue. We do not expect any issues with our product supply as a result of these negotiations or the notice of termination.

Other Information

As discussed in Note 15 -- Commitments and Contingencies and Part II -- Item 1 -- Legal Proceedings, Monsanto is involved in a number of lawsuits and claims relating to a variety of issues. Many of these lawsuits relate to intellectual property disputes. We expect that such disputes will continue to occur as the agricultural biotechnology industry evolves.

As mentioned in the "Overview -- Executive Summary -- Outlook" section of MD&A, we are required to indemnify Pharmacia for Solutia's Assumed Liabilities. Our obligation to indemnify Pharmacia for Solutia's Assumed Liabilities is discussed in Note 15.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

For additional information on the outlook for Monsanto, see "Cautionary Statements Regarding Forward-Looking Statements" contained in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, and Part II -- Item 1A -- Risk Factors of this Form 10-Q.

40

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

In preparing our financial statements, we must select and apply various accounting policies. Our most significant policies are described in Part II -- Item 8 -- Note 2 -- Significant Accounting Policies -- to the consolidated financial statements contained in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005. In order to apply our accounting policies, we often need to make estimates based on judgments about future events. In making such estimates, we rely on historical experience, market and other conditions, and on assumptions that we believe to be reasonable. However, the estimation process is, by its nature, uncertain given that estimates depend on events over which we may not have control. If market and other conditions change from those that we anticipate, our financial condition, results of operations, or liquidity may be affected materially. In addition, if our assumptions change, we may need to revise our estimates, or take other corrective actions, either of which may have a material effect on our financial condition, results of operations, or liquidity.

The estimates that have a higher degree of inherent uncertainty and require our most significant judgments are outlined in Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our Report on Form 10-K for fiscal year ended Aug. 31, 2005. Had we used estimates different from any of those contained in such Report on Form 10-K, our financial condition, profitability, or liquidity for the current period could have been materially different from those presented.

NEW ACCOUNTING STANDARDS

In September 2005, the FASB reached a final consensus on EITF Issue No. 04-13, Accounting for Purchases and Sales of Inventory with the Same Counterparty (EITF 04-13). EITF 04-13 concludes that two or more legally separate exchange transactions with the same counterparty should be combined and considered as a single arrangement for purposes of applying APB Opinion No. 29, Accounting for Nonmonetary Transactions, when the transactions were entered into in contemplation of one another. The consensus contains several indicators to be considered in assessing whether two transactions are entered into in contemplation of one another. If, based on consideration of the indicators and the substance of the arrangement, two transactions are combined and considered a single arrangement, an exchange of finished goods inventory for either raw material inventory or work-in-process inventory should be accounted for at fair value. The provisions of EITF 04-13 are effective for transactions beginning in our fourth quarter 2006. We are currently evaluating the impact of EITF 04-13 on the consolidated financial statements.

In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections (SFAS 154). SFAS 154 requires retrospective application to prior-period financial statements of changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

cumulative effect of the change. SFAS 154 also redefines "restatement" as the revising of previously issued financial statements to reflect the correction of an error. This statement is effective for accounting changes and corrections of errors made in fiscal years beginning after Dec. 15, 2005. We do not believe that the adoption of SFAS 154 will have a material impact on the consolidated financial statements.

In March 2005, the FASB issued Interpretation No. 47, Accounting for Conditional Asset Retirement Obligations (FIN 47), to clarify the term "conditional asset retirement" as used in SFAS 143, Accounting for Asset Retirement Obligations. FIN 47 requires that a liability be recognized for the fair value of a conditional asset retirement obligation when incurred, if the fair value of the liability can be reasonably estimated. Uncertainty about the timing or method of settlement of a conditional asset retirement obligation would be factored into the measurement of the liability when sufficient information exists. This interpretation is effective no later than the end of fiscal years ending after Dec. 15, 2005. Accordingly, we will adopt FIN 47 no later than fourth quarter of fiscal year 2006. We do not believe that the adoption of FIN 47 will have a material impact on the consolidated financial statements.

In December 2004, the FASB issued FASB Staff Position No. 109-1, Application of FASB Statement No. 109 (SFAS 109), Accounting for Income Taxes, to the Tax Deduction on Qualified Production Activities Provided by the American Jobs Creation Act of 2004 (FSP 109-1). FSP 109-1 clarifies that the manufacturer's deduction provided for under the American Jobs Creation Act of 2004 (AJCA) should be accounted for as a special deduction in accordance with SFAS 109 and not as a tax rate reduction. The adoption of FSP 109-1 had no impact on our consolidated financial statements in 2005 because the manufacturer's deduction is not available to us until fiscal year 2006. We are currently evaluating the effect that the manufacturer's deduction will have in 2006 and subsequent years. The FASB also issued FASB Staff Position No. 109-2, Accounting and Disclosure Guidance for the Foreign Earnings Repatriation Provision within the American

41

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

Jobs Creation Act of 2004 (FSP 109-2). The AJCA introduced a special one-time dividends received deduction on the repatriation of certain foreign earnings to a U.S. taxpayer (repatriation provision), provided certain criteria are met. FSP 109-2 provides accounting and disclosure guidance for the repatriation provision. The range of possible amounts that we are currently considering eligible for repatriation is between zero and \$500 million. See Note 8 -- Income Taxes -- for additional disclosures in accordance with FSP 109-2.

Accounting Guidance Adopted in First Quarter 2006:

In December 2004, the FASB issued SFAS No. 123 (revised 2004), Share-Based Payment (SFAS 123R). SFAS 123R replaced SFAS No. 123, Accounting for Stock-Based Compensation, and superseded APB Opinion No. 25, Accounting for Stock Issued to Employees. In March 2005, the SEC issued Staff Accounting Bulletin No. 107, which expresses views of the SEC staff regarding the interaction between SFAS 123R and certain SEC rules and regulations, and provides the staff's views regarding the valuation of share-based payment arrangements for public companies. On Sept. 1, 2005, we adopted SFAS 123R, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors based on estimated fair values. We adopted SFAS 123R using the modified prospective transition method. Under this method, our consolidated financial statements as of and for the three months ended Nov. 30, 2005, reflect the impact of SFAS 123R, while the consolidated financial statements for prior periods have not been restated to reflect, and do

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

not include, the impact of SFAS 123R. Stock-based compensation expense recognized under SFAS 123R was \$13 million for first quarter 2006 (including \$3 million related to share-based awards for which compensation expense was being recognized prior to the adoption of SFAS 123R).

Upon adoption of SFAS 123R, we began estimating the value of employee stock options on the date of grant using a lattice-binomial model. Prior to adoption of SFAS 123R, the value of employee stock options was estimated on the date of grant using the Black-Scholes model, for the disclosures of pro forma financial information required under SFAS 123. Pre-tax unrecognized compensation expense, net of estimated forfeitures, for stock options, nonvested restricted stock and nonvested restricted stock units was \$99 million as of Nov. 30, 2005, which will be recognized over weighted-average periods of two to three years. See Note 11 -- Stock-Based Compensation Plans-- for pro forma disclosure of stock-based compensation expense for first quarter 2005 and additional disclosures in accordance with SFAS 123R.

In November 2004, the FASB issued SFAS No. 151, Inventory Costs -- an amendment of ARB No. 43, Chapter 4 (SFAS 151), to clarify that abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage) should be recognized as current period charges and to require the allocation of fixed production overhead to the costs of conversion based on the normal capacity of the production facilities. SFAS 151 was effective prospectively for our inventory costs incurred after Sept. 1, 2005. The adoption of SFAS 151 did not have a material impact on our consolidated financial statements.

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Report on Form 10-Q are "forward-looking statements," such as statements concerning the company's anticipated financial results, current and future product performance, regulatory approvals, business and financial plans and other non-historical facts. These statements are based on current expectations and currently available information. However, since these statements are based on factors that involve risks and uncertainties, the company's actual performance and results may differ materially from those described or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, among others: continued competition in seeds, traits and agricultural chemicals; the company's exposure to various contingencies, including those related to intellectual property protection, regulatory compliance and the speed with which approvals are received, and public acceptance of biotechnology products; the success of the company's research and development activities; the outcomes of major lawsuits, including proceedings related to Solutia Inc.; developments related to foreign currencies and economies; successful completion and operation of recent and proposed acquisitions; fluctuations in commodity prices; compliance with regulations affecting our manufacturing; the accuracy of the company's estimates related to distribution inventory levels; the company's ability to fund its short-term financing needs and to obtain payment for the products that it sells; the effect of weather conditions, natural disasters and accidents on the agriculture business or the company's facilities; and other risks and factors detailed in the company's Report on Form 10-K for the fiscal year ended Aug. 31, 2005, filed with the SEC. Undue reliance should not be placed on these forward-looking statements, which are current only as of the date of this report. The company disclaims any current intention or obligation to update any forward-looking statements or any of the factors that may affect actual results. See "MD&A -- Cautionary Statements Regarding Forward-Looking Statements," in

Part II -- Item 7 of our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, for a further discussion regarding some of the reasons that actual results may be materially different from those that we anticipate.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There are no material changes related to market risk from the disclosures in Monsanto's Report on Form 10-K for the fiscal year ended Aug. 31, 2005.

ITEM 4. CONTROLS AND PROCEDURES

We maintain a comprehensive set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported accurately and within the time periods specified in the SEC's rules and forms. As of Nov. 30, 2005 (the Evaluation Date), an evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the Evaluation Date, the design and operation of these disclosure controls and procedures were effective to provide reasonable assurance of the achievement of the objectives described above.

During the quarter that ended on the Evaluation Date, there was no change in internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

43

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

PART II--OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

This section of the Report on Form 10-Q provides information regarding material legal proceedings that we are defending or prosecuting. These include proceedings to which we are party in our own name and proceedings to which Pharmacia is a party but that we manage and for which we are responsible, and proceedings that we are managing related to Solutia's Assumed Liabilities. Information regarding certain legal proceeding and the possible effects on our business of litigation we are defending is disclosed in Note 15 under the subheading "Litigation and Indemnification" and is incorporated by reference herein. We are also defending or prosecuting other legal proceedings, not described in this section, which arise in the ordinary course of our business. We believe we have meritorious legal arguments and will continue to represent our interests vigorously in all of the proceedings that we are defending or prosecuting.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

The following discussion provides new and updated information regarding certain proceedings to which Pharmacia or Monsanto is a party and for which we are responsible. Other information with respect to legal proceedings appears in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005.

Patent and Commercial Proceedings

The following proceedings involve Syngenta AG and its affiliates:

- o As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, on May 10, 2004, we filed suit against Syngenta Seeds in the Circuit Court of St. Louis County, Missouri, for declaratory judgment seeking a determination that, under its license from us for ROUNDUP READY soybeans, Syngenta Seeds is limited to commercializing its ROUNDUP READY soybeans under one product brand. On Dec. 20, 2005, the court conducted a bench trial. The case is now under submission and a decision is pending.
- o As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, on Aug. 25, 2005, Syngenta filed suit against us in the Circuit Court of Hennepin County, Minnesota, seeking access to our new patented next generation glyphosate-tolerant soybean technology under a license for our current soybean technology that we previously entered into with Ciba Seeds, which is now owned by Syngenta. This case has no trial setting.

As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, on July 26, 2005, American Seed Company filed a purported class action against us in the U.S. District Court for the District of Delaware, supposedly on behalf of direct purchasers of corn seed containing our transgenic traits. American Seed essentially alleges that we have monopolized or attempted to monopolize markets for glyphosate-tolerant corn seed, European corn borer-protected corn seed and foundation corn seed. Plaintiffs seek an unspecified amount of damages and injunctive relief. On Dec. 6, 2005, the court denied our motion to transfer the case to the U.S. District Court for the Eastern District of Missouri and to consolidate it with an action we already have pending against American Seed for unpaid royalties. This case has been set for trial on Oct. 15, 2007.

Grower Lawsuits

As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, on Feb. 14, 2000, a lawsuit (Randy Blades, et al v. Monsanto Company, Cause No. 00-403JLF) was filed in U.S. District Court for the Southern District of Illinois, on behalf of five farmers purporting to represent various classes of farmers and alleging that we and others violated antitrust laws by allegedly fixing the price of seed containing biotech traits and violated tort and international law through the commercialization of biotech traits. After the lawsuit was transferred to the U.S. District Court for the Eastern District of Missouri, the District Court granted our motion for summary judgment on all the plaintiffs' tort claims, including all claims relating to alleged violations of law. The District Court also denied the plaintiffs' motion to certify for class action status the plaintiffs' claims that we and the other defendants have violated various antitrust laws, which decision was affirmed by the U.S. Court of Appeals for the Eighth Circuit. On Nov. 9, 2005, the District Court denied the plaintiffs' motion seeking to certify a class only of growers of glyphosate-tolerant soybeans from the states of Minnesota, Iowa, Illinois and Indiana.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Agent Orange Proceedings

As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, certain Korean veterans of the Vietnam War have filed suit in Seoul, South Korea, against The Dow Chemical Company and the former Monsanto Company. Plaintiffs allege that they were exposed to herbicides, and that they suffered injuries or their children suffered birth defects as a result. Three separate complaints filed in October 1999 are being handled collectively and currently involve approximately 16,700 plaintiffs. The complaints seek damages of 300 million won (approximately \$287,000) per plaintiff. In 2002, the Seoul District Court ruled in favor of the manufacturers and dismissed all claims of the plaintiffs on the basis of lack of causation and statutes of limitations. Plaintiffs have filed an appeal de novo with the Seoul High Court and the parties have engaged in the briefing process required by that court. At its last formal hearing on Dec. 27, 2005, the Court announced that it will issue its decision in this matter on Jan. 26, 2006.

Proceedings Regarding Tax Matters

On Dec. 2, 2005, the Federal Revenue Service of the Ministry of Finance of Brazil issued a tax assessment against our wholly owned subsidiary, Monsanto do Brasil Ltda., challenging the tax treatment of \$575 million of notes issued in 1998. The tax assessment reflects the view of the Federal Revenue Service that the transactions involving the notes represented contributions to the capital of Monsanto do Brasil rather than funding through issuance of notes. The assessment denies tax deductions for approximately \$915 million (subject to currency exchange rates) of interest expense and currency exchange losses that were claimed by Monsanto do Brasil under the notes. The assessment seeks payment of approximately \$42 million of tax, excluding penalties and interest, related to the notes (subject to currency exchange rates), and would preclude Monsanto do Brasil from using a net operating loss carryforward of approximately \$800 million (subject to currency exchange rates). The issuance of the notes was properly registered with the Central Bank of Brazil and we believe that there is no basis in law for this tax assessment. On Dec. 29, 2005, Monsanto do Brasil filed an appeal of this assessment with the Federal Revenue Service. Under the terms of a tax sharing agreement concluded with Pharmacia at the time of our separation from Pharmacia, Pharmacia would be responsible for a portion of any liability incurred by virtue of the tax assessment. All dollar amounts have been calculated based on an exchange rate of 2.207 Brazilian reais per U.S. dollar, and will fluctuate with exchange rates in the future.

Proceedings Related to Solutia's Assumed Liabilities

On Dec. 6, 2005, a products liability lawsuit was filed against Monsanto, Pharmacia Corporation, and Solutia Inc. in the Supreme Court of New York County, New York. The suit claims that all defendants manufactured and sold PCB products to General Electric Company and is brought by 590 current employees of General Electric who allege exposure to chemicals used by General Electric in and around its plant in Schenectady, New York from the 1970s to the present. The suit seeks actual and punitive damages for alleged personal injuries and fear of future disease.

See Note 15 for additional information regarding legal proceedings related to Solutia's Assumed Liabilities.

See "MD&A -- Cautionary Statements Regarding Forward-Looking Statements," in Part I -- Item 2 of this Report on Form 10-Q and in Part II -- Item 7 of our Report on Form 10-K for the fiscal year ended Aug. 31, 2005, which are incorporated herein by reference, for information regarding the risk factors that may affect any forward-looking statements regarding our legal proceedings.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

ITEM 1A. RISK FACTORS

Information regarding risk factors appears in "MD&A -- Cautionary Statements Regarding Forward-Looking Statements," in Part I -- Item 2 of this Report on Form 10-Q and in Part II -- Item 7 of our Report on Form 10-K for the fiscal year ended Aug. 31, 2005. There have been no material changes from the risk factors previously disclosed in our Report on Form 10-K.

45

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table is a summary of any purchases of equity securities during the first quarter of fiscal year 2006 by Monsanto and any affiliated purchasers, pursuant to SEC rules.

Period	(a) Total Number of Shares Purchased	(b) Average Price Paid per Share(1)	(c) T Purc o Ann o
September 2005:			
Sept. 1, 2005, through Sept. 30, 2005	32,610 (2)	\$ 63.53	
October 2005:			
Oct. 1, 2005, through Oct. 31, 2005	7,842 (2)	\$ 60.26	
November 2005:			
Nov. 1, 2005, through Nov. 30, 2005	--	\$ --	
Total	40,452	\$ 62.90	

- (1) The average price paid per share is calculated on a settlement basis and excludes commission.
- (2) Represents total number of restricted shares withheld to cover the withholding taxes upon the vesting of restricted stock.

On Oct. 25, 2005, the board of directors authorized the purchase of up to \$800 million of the company's common stock over a four-year period. The plan expires on Oct. 25, 2009. There were no other publicly announced plans outstanding as of Nov. 30, 2005.

ITEM 5. OTHER INFORMATION

RELATIONSHIPS AMONG MONSANTO COMPANY, PHARMACIA CORPORATION, PFIZER INC. AND SOLUTIA INC.

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

Prior to Sept. 1, 1997, a corporation that was then known as Monsanto Company (Former Monsanto) operated an agricultural products business (the Ag Business), a pharmaceuticals and nutrition business (the Pharmaceuticals Business) and a chemical products business (the Chemicals Business). Former Monsanto is today known as Pharmacia. Pharmacia is now a wholly owned subsidiary of Pfizer Inc., which together with its subsidiaries operates the Pharmaceuticals Business. Our business includes the operations, assets and liabilities that were previously the Ag Business. Solutia comprises the operations, assets and liabilities that were previously the Chemicals Business. The following table sets forth a chronology of events that resulted in the formation of Monsanto, Pharmacia and Solutia as three separate and distinct corporations, and provides a brief background on the relationships among these corporations.

Date of Event	Description of Event
Sept. 1, 1997	<ul style="list-style-type: none"> o Pharmacia (then known as Monsanto Company) entered into Agreement (Distribution Agreement) with Solutia related operations, assets and liabilities of the Chemicals Business (then known as Monsanto Company) to Solutia. o Pursuant to the Distribution Agreement, Solutia assumed (then known as Monsanto Company) for certain liabilities Business.
Dec. 19, 1999	<ul style="list-style-type: none"> o Pharmacia (then known as Monsanto Company) entered into Pharmacia & Upjohn, Inc. (PNU) relating to a merger (th
Feb. 9, 2000	<ul style="list-style-type: none"> o We were incorporated in Delaware as a wholly owned subsidiary (then known as Monsanto Company) under the name "Monsan
March 31, 2000	<ul style="list-style-type: none"> o Effective date of the Merger. o In connection with the Merger, (1) PNU became a wholly Pharmacia (then known as Monsanto Company); (2) Pharmacia Monsanto Company) changed its name from "Monsanto Company Corporation;" and (3) we changed our name from "Monsanto "Monsanto Company."

46

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

Sept. 1, 2000	<ul style="list-style-type: none"> o We entered into a Separation Agreement (Separation Agreement) Pharmacia related to the transfer of the operations, as the Ag Business from Pharmacia to us. o Pursuant to the Separation Agreement, we were required liabilities primarily related to the Ag Business or the liabilities assumed by Solutia pursuant to the Distribution Agreement. Solutia fails to pay, perform or discharge those liabilities
Oct. 23, 2000	<ul style="list-style-type: none"> o We completed an initial public offering in which we sold percent of the shares of our common stock to the public own 220 million shares of our common stock.
July 1, 2002	<ul style="list-style-type: none"> o Pharmacia, Solutia and we amended the Distribution Agreement

Edgar Filing: MONSANTO CO /NEW/ - Form 10-Q

- Aug. 13, 2002

 - o that Solutia will indemnify us for the same liabilities to indemnify Pharmacia and to clarify the parties' rights
 - o Pharmacia and we amended the Separation Agreement to clarify obligations relating to our indemnification obligations
- Aug. 13, 2002

 - o Pharmacia distributed the 220 million shares of our common stock owned to its shareowners via a tax-free stock dividend
 - o As a result of the Monsanto Spinoff, Pharmacia no longer has an interest in Monsanto.
- April 16, 2003

 - o Pursuant to a merger transaction, Pharmacia became a wholly owned subsidiary of Pfizer.
- Dec. 17, 2003

 - o Solutia and 14 of its U.S. subsidiaries filed a voluntary reorganization under Chapter 11 of the U.S. Bankruptcy Code

Part II -- Item 1 -- Legal Proceedings includes information concerning litigation matters that Monsanto is managing pursuant to its obligation under the Separation Agreement to indemnify Pharmacia. Note 15 includes further information regarding litigation and environmental matters that we are managing pursuant to our obligation under the Separation Agreement to indemnify Pharmacia, Solutia's bankruptcy, the related charge we recorded associated with certain of Solutia's litigation and environmental obligations, and other arrangements between Solutia and us.

ITEM 6. EXHIBITS

Exhibits: The list of exhibits in the Exhibit Index to this Report is incorporated herein by reference.

47

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MONSANTO COMPANY
(Registrant)

By: /s/ RICHARD B. CLARK

Richard B. Clark
Vice President and Controller
(On behalf of the Registrant and as
Principal Accounting Officer)

Date: Jan. 9, 2006

48

MONSANTO COMPANY

FIRST QUARTER 2006 FORM 10-Q

EXHIBIT INDEX

These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K.

Exhibit No.	Description
2	Omitted
3	Omitted
4	Omitted
10	Omitted
11	Omitted -- see Note 13 of Notes to Consolidated Financial Statements -- Earnings
12	Computation of Ratio of Earnings to Fixed Charges.
15	Omitted
18	Omitted
19	Omitted
22	Omitted
23	Omitted
24	Omitted
31.1	Rule 13a-14(a)/15d-14(a) Certification (pursuant to Section 302 of the Sarbanes Oxley Act of 2002, executed by the Chief Executive Officer).
31.2	Rule 13a-14(a)/15d-14(a) Certification (pursuant to Section 302 of the Sarbanes Oxley Act of 2002, executed by the Chief Financial Officer).
32	Rule 13(a)-14(b) Certifications (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by the Chief Executive Officer and the Chief Financial Officer).